<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Nature</publisher>
				<availability status="unknown"><p>Copyright Springer Nature</p>
				</availability>
				<date type="published" when="2014-10-30">30 October 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Köbel</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Madore</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">University of British Columbia</orgName>
								<orgName type="institution" key="instit2">BC Cancer Agency</orgName>
								<address>
									<addrLine>600 West 10th Avenue</addrLine>
									<postCode>V5E 4E6</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Melanoma Institute Australia</orgName>
								<orgName type="institution" key="instit2">University of Sydney</orgName>
								<orgName type="institution" key="instit3">Royal Prince Alfred Hospital</orgName>
								<address>
									<addrLine>Gloucester House-level 3, Missenden Road</addrLine>
									<postCode>2050</postCode>
									<settlement>Camperdown</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">USC/Norris Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit1">Keck School of Medicine</orgName>
								<orgName type="institution" key="instit2">University of Southern California</orgName>
								<orgName type="institution" key="instit3">Harlyne Norris Research Tower</orgName>
								<address>
									<addrLine>1450 Biggy Street, Office 2517G</addrLine>
									<postCode>90033</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Laboratory Medicine and Pathobiology</orgName>
								<orgName type="department" key="dep2">Princess Margaret Cancer Centre</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>610 Univeristy Avenue</addrLine>
									<postCode>M-700, M5T 2M9</postCode>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">D P</forename><surname>Pharoah</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Deen</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Histopathology</orgName>
								<orgName type="department" key="dep2">Queen&apos;s Medical Centre</orgName>
								<orgName type="institution">Nottingham University Hospitals NHS Trust</orgName>
								<address>
									<postCode>NG7 2UH</postCode>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Bowtell</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Cancer Genomics and Genetics</orgName>
								<orgName type="department" key="dep2">Peter MacCallum Cancer Centre</orgName>
								<address>
									<addrLine>Locked Bag I, A&apos;Beckett Street, East Melbourne</addrLine>
									<postCode>8006</postCode>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Department of Biochemistry and Molecular Biology</orgName>
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<addrLine>30 Flemington Road</addrLine>
									<postCode>3010</postCode>
									<settlement>Melbourne</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Sir Peter MacCallum</orgName>
								<orgName type="institution" key="instit2">University of Melbourne</orgName>
								<address>
									<addrLine>30 Flemington Road</addrLine>
									<postCode>3010</postCode>
									<settlement>Melbourne</settlement>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Odunsi</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Gynecological Oncology</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Menon</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Gynaecological Cancer Research Centre</orgName>
								<orgName type="department" key="dep2">Department of Women&apos;s Cancer</orgName>
								<orgName type="department" key="dep3">Institute for Women&apos;s Health</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<addrLine>Maple House 1st Floor, 149 Tottenham Court Road</addrLine>
									<postCode>W1T 7DN</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Morrison</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lele</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Department of Gynecological Oncology</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Cancer Prevention and Control</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Bshara</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sucheston</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Cancer Prevention and Control</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">W</forename><surname>Beckmann</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hein</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">C</forename><surname>Thiel</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hartmann</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Erlangen</orgName>
								<address>
									<addrLine>Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Krankenhausstrasse 8-10</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Wachter</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Erlangen</orgName>
								<address>
									<addrLine>Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Krankenhausstrasse 8-10</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Anglesio</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Høgdall</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">University of British Columbia</orgName>
								<orgName type="institution" key="instit2">BC Cancer Agency</orgName>
								<address>
									<addrLine>600 West 10th Avenue</addrLine>
									<postCode>V5E 4E6</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Department of Virus, Lifestyle and Genes</orgName>
								<orgName type="department" key="dep2">Danish Cancer Society Research Center</orgName>
								<address>
									<addrLine>Strandboule-varden 49</addrLine>
									<postCode>DK-2100</postCode>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Department of Pathology, Herlev Hospital</orgName>
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<addrLine>Herlev Ringvej 75</addrLine>
									<postCode>DK-2370</postCode>
									<settlement>Herlev</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Jensen</surname></persName>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Department of Virus, Lifestyle and Genes</orgName>
								<orgName type="department" key="dep2">Danish Cancer Society Research Center</orgName>
								<address>
									<addrLine>Strandboule-varden 49</addrLine>
									<postCode>DK-2100</postCode>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Høgdall</surname></persName>
							<affiliation key="aff20">
								<orgName type="department" key="dep1">The Juliane Marie Center</orgName>
								<orgName type="department" key="dep2">Department of Obstetrics and Gynecology, Rigshospitalet</orgName>
								<orgName type="institution">University of Copenhagen</orgName>
								<address>
									<addrLine>Blegdamsvej 9</addrLine>
									<postCode>DK-2100</postCode>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW, Charlton 6, Rochester</addrLine>
									<postCode>55905</postCode>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Fridley</surname></persName>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Department of Biostatistics</orgName>
								<orgName type="department" key="dep2">Medical Center</orgName>
								<orgName type="department" key="dep3">Rainbow Boulevard, Kansas City</orgName>
								<orgName type="institution">University of Kansas</orgName>
								<address>
									<postCode>3901, 66160</postCode>
									<region>KS</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
							<affiliation key="aff23">
								<orgName type="department" key="dep1">Department of Laboratory Medicine and Pathology</orgName>
								<orgName type="department" key="dep2">Division of Anatomic Pathology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW, Stabile 13, Rochester</addrLine>
									<postCode>55905</postCode>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">C</forename><surname>Fogarty</surname></persName>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Department of Health Sciences Research</orgName>
								<orgName type="department" key="dep2">Division of Biomedical Statistics and Informatics</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW, Charlton 6, Rochester</addrLine>
									<postCode>55905</postCode>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Vierkant</surname></persName>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Department of Health Sciences Research</orgName>
								<orgName type="department" key="dep2">Division of Biomedical Statistics and Informatics</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW, Charlton 6, Rochester</addrLine>
									<postCode>55905</postCode>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Liu</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Foothills Medical Center</orgName>
								<orgName type="laboratory">Anatomic Pathology Research Laboratory, Calgary Laboratory Services</orgName>
								<address>
									<addrLine>1403 29 ST NW</addrLine>
									<postCode>T2N 2T9</postCode>
									<settlement>Calgary</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cho</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">Foothills Medical Center</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<addrLine>1403 29 ST NW</addrLine>
									<postCode>T2N 2T9</postCode>
									<settlement>Calgary</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Nelson</surname></persName>
							<affiliation key="aff26">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Division of Oncology, Tom Baker Cancer Centre</orgName>
								<orgName type="department" key="dep3">Foothills Medical Center</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<addrLine>1403 29 ST NW</addrLine>
									<postCode>T2N 2T9</postCode>
									<settlement>Calgary</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ghatage</surname></persName>
							<affiliation key="aff26">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Division of Oncology, Tom Baker Cancer Centre</orgName>
								<orgName type="department" key="dep3">Foothills Medical Center</orgName>
								<orgName type="institution">University of Calgary</orgName>
								<address>
									<addrLine>1403 29 ST NW</addrLine>
									<postCode>T2N 2T9</postCode>
									<settlement>Calgary</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Gentry-Maharaj</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Gynaecological Cancer Research Centre</orgName>
								<orgName type="department" key="dep2">Department of Women&apos;s Cancer</orgName>
								<orgName type="department" key="dep3">Institute for Women&apos;s Health</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<addrLine>Maple House 1st Floor, 149 Tottenham Court Road</addrLine>
									<postCode>W1T 7DN</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">USC/Norris Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit1">Keck School of Medicine</orgName>
								<orgName type="institution" key="instit2">University of Southern California</orgName>
								<orgName type="institution" key="instit3">Harlyne Norris Research Tower</orgName>
								<address>
									<addrLine>1450 Biggy Street, Office 2517G</addrLine>
									<postCode>90033</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Benjamin</surname></persName>
							<affiliation key="aff27">
								<orgName type="department">Department of Pathology, Cancer Institute</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<addrLine>Maple House, 149 Tottenham Court Road</addrLine>
									<postCode>WC1E 6JJ</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Widschwendter</surname></persName>
							<affiliation key="aff28">
								<orgName type="department">Department of Women&apos;s Cancer, UCL EGA Institute for Womeń s Health</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<addrLine>74 Huntley Street</addrLine>
									<postCode>WC1E 6AU</postCode>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Intermaggio</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Rosen</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Preventive Medicine</orgName>
								<orgName type="department" key="dep2">USC/Norris Comprehensive Cancer Center</orgName>
								<orgName type="institution" key="instit1">Keck School of Medicine</orgName>
								<orgName type="institution" key="instit2">University of Southern California</orgName>
								<orgName type="institution" key="instit3">Harlyne Norris Research Tower</orgName>
								<address>
									<addrLine>1450 Biggy Street, Office 2517G</addrLine>
									<postCode>90033</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>Princess Margaret Cancer Centre, 610 University Avenue, M-700, Toronto</addrLine>
									<postCode>M5T 2M9</postCode>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Q</forename><surname>Bernardini</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>Princess Margaret Cancer Centre, 610 University Avenue, M-700, Toronto</addrLine>
									<postCode>M5T 2M9</postCode>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Mackay</surname></persName>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Division of Medical Oncology</orgName>
								<orgName type="department" key="dep3">Princess Margaret Hospital</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>610 University Avenue</addrLine>
									<postCode>M5G 2M9</postCode>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Oza</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>Princess Margaret Cancer Centre, 610 University Avenue, M-700, Toronto</addrLine>
									<postCode>M5T 2M9</postCode>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Shaw</surname></persName>
							<affiliation key="aff29">
								<orgName type="department">Department of Obstetrics and Gynecology</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<addrLine>Princess Margaret Cancer Centre, 610 University Avenue, M-700, Toronto</addrLine>
									<postCode>M5T 2M9</postCode>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Jimenez-Linan</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Department of Pathology, Addenbrooke&apos;s Hospital</orgName>
								<orgName type="institution">Cambridge University Hospital NHS Foundation Trust</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0QQ</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Biomedical Research Centre</orgName>
								<orgName type="institution">National Institute for Health Research Cambridge</orgName>
								<address>
									<postCode>CB2 2QQ</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Driver</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="laboratory">Strangeways Research Laboratory</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<addrLine>Worts Causeway</addrLine>
									<postCode>CB1 8RN</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Alsop</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="laboratory">Strangeways Research Laboratory</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<addrLine>Worts Causeway</addrLine>
									<postCode>CB1 8RN</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mack</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="laboratory">Strangeways Research Laboratory</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<addrLine>Worts Causeway</addrLine>
									<postCode>CB1 8RN</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Koziak</surname></persName>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Department of Population Health Research</orgName>
								<orgName type="department" key="dep2">Alberta Health Services-Cancer Care</orgName>
								<address>
									<addrLine>2210 2nd Street SW, Calgary</addrLine>
									<postCode>T2S 3C3</postCode>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Steed</surname></persName>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Division of Gynecologic Oncology, Royal Alexandra Hospital</orgName>
								<address>
									<addrLine>10240 Kingsway Ave, Edmonton</addrLine>
									<postCode>T5H 3V9</postCode>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ewanowich</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Department of Laboratory Medicine and Pathology</orgName>
								<orgName type="institution">Royal Alexandra Hospital</orgName>
								<address>
									<addrLine>10240 Kingsway Ave, Edmonton</addrLine>
									<postCode>T5H 3V9</postCode>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Defazio</surname></persName>
							<affiliation key="aff36">
								<orgName type="department">Department of Gynaecological Oncology and Westmead Institute for Cancer Research</orgName>
								<orgName type="institution">University of Sydney at Westmead Millennium Institute</orgName>
								<address>
									<addrLine>Westmead Hospital, Westmead</addrLine>
									<postCode>2145</postCode>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Chenevix-Trench</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute</orgName>
								<address>
									<addrLine>300 Herston Road</addrLine>
									<postCode>4006</postCode>
									<settlement>Herston</settlement>
									<region>QLD</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fereday</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Cancer Genomics and Genetics</orgName>
								<orgName type="department" key="dep2">Peter MacCallum Cancer Centre</orgName>
								<address>
									<addrLine>Locked Bag I, A&apos;Beckett Street, East Melbourne</addrLine>
									<postCode>8006</postCode>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Gao</surname></persName>
							<affiliation key="aff36">
								<orgName type="department">Department of Gynaecological Oncology and Westmead Institute for Cancer Research</orgName>
								<orgName type="institution">University of Sydney at Westmead Millennium Institute</orgName>
								<address>
									<addrLine>Westmead Hospital, Westmead</addrLine>
									<postCode>2145</postCode>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Johnatty</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute</orgName>
								<address>
									<addrLine>300 Herston Road</addrLine>
									<postCode>4006</postCode>
									<settlement>Herston</settlement>
									<region>QLD</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>George</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Cancer Genomics and Genetics</orgName>
								<orgName type="department" key="dep2">Peter MacCallum Cancer Centre</orgName>
								<address>
									<addrLine>Locked Bag I, A&apos;Beckett Street, East Melbourne</addrLine>
									<postCode>8006</postCode>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Galletta</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Cancer Genomics and Genetics</orgName>
								<orgName type="department" key="dep2">Peter MacCallum Cancer Centre</orgName>
								<address>
									<addrLine>Locked Bag I, A&apos;Beckett Street, East Melbourne</addrLine>
									<postCode>8006</postCode>
									<region>VIC</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Goode</surname></persName>
							<affiliation key="aff38">
								<orgName type="department" key="dep1">Department of Health Sciences Research</orgName>
								<orgName type="department" key="dep2">Division of Epidemiology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW Charlton 6, Rochester</addrLine>
									<postCode>55905</postCode>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K</forename><surname>Kjær</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Pathology and Laboratory Medicine</orgName>
								<orgName type="institution" key="instit1">University of British Columbia</orgName>
								<orgName type="institution" key="instit2">BC Cancer Agency</orgName>
								<address>
									<addrLine>600 West 10th Avenue</addrLine>
									<postCode>V5E 4E6</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
							<affiliation key="aff39">
								<orgName type="department">Centre For Translational and Applied Genomics, British Columbia Cancer Agency</orgName>
								<address>
									<addrLine>600 West 10th Avenue</addrLine>
									<postCode>V5Z 4E6</postCode>
									<settlement>Vancouver</settlement>
									<region>BC</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Fasching</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Gynecology</orgName>
							</affiliation>
							<affiliation key="aff40">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep3">David Geffen School of Medicine, University of California at Los Angeles</orgName>
								<address>
									<postCode>90095</postCode>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">B</forename><surname>Moysich</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Department of Cancer Prevention and Control</orgName>
								<orgName type="department" key="dep2">Roswell Park Cancer Institute, Elm and Carlton Streets</orgName>
								<address>
									<postCode>14263</postCode>
									<settlement>Buffalo</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Brenton</surname></persName>
							<affiliation key="aff32">
								<orgName type="department">Biomedical Research Centre</orgName>
								<orgName type="institution">National Institute for Health Research Cambridge</orgName>
								<address>
									<postCode>CB2 2QQ</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff41">
								<orgName type="department" key="dep1">Department of Oncology</orgName>
								<orgName type="department" key="dep2">Hutchison/MRC Research Centre</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0XZ</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff42">
								<orgName type="department">Cancer Research UK Cambridge Institute</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<addrLine>Li Ka Shing Centre, Robinson Way</addrLine>
									<postCode>CB2 0RE</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff43">
								<orgName type="department">Cambridge Experimental Cancer Medicine Centre</orgName>
								<address>
									<postCode>CB2 0RE</postCode>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">L</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
							<email>kelemen@musc.edu</email>
							<affiliation key="aff44">
								<orgName type="department">Department of Public Health Sciences, Medical University of South Carolina and Hollings Cancer Center</orgName>
								<address>
									<addrLine>135 Cannon Street</addrLine>
									<postCode>29425</postCode>
									<settlement>Charleston</settlement>
									<region>SC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="institution">University Hospital Erlangen</orgName>
								<address>
									<addrLine>Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Universitaetsstrasse 21-23</addrLine>
									<postCode>91054</postCode>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study</title>
					</analytic>
					<monogr>
						<title level="j" type="main">British Journal of Cancer</title>
						<title level="j" type="abbrev">Br J Cancer</title>
						<idno type="ISSN">0007-0920</idno>
						<idno type="eISSN">1532-1827</idno>
						<imprint>
							<publisher>Springer Nature</publisher>
							<biblScope unit="volume">111</biblScope>
							<biblScope unit="issue">12</biblScope>
							<biblScope unit="page" from="2297" to="2307"/>
							<date type="published" when="2014-10-30">30 October 2014</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1038/bjc.2014.567</idno>
					<idno type="PMID">25349970</idno>
					<idno type="PMCID">PMC4264456</idno>
					<ptr type="open-access" target="https://www.nature.com/articles/bjc2014567.pdf" />
					<note type="submission">Revised 3 September 2014; accepted 2 October 2014;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T21:54+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>ovarian cancer</term>
					<term>folate receptor alpha</term>
					<term>FRA</term>
					<term>immunohistochemistry</term>
					<term>prognosis</term>
					<term>TCGA</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical trials testing anti-FOLR1 therapies in OvCa show mixed results and require better understanding of the prognostic relevance of FOLR1 expression. We conducted a large study evaluating FOLR1 expression with survival in different histological types of OvCa.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Methods: Tissue microarrays composed of tumour samples from 2801 patients in the Ovarian Tumour Tissue Analysis (OTTA) consortium were assessed for FOLR1 expression by centralised immunohistochemistry. We estimated associations for overall (OS) and progression-free (PFS) survival using adjusted Cox regression models. High-grade serous ovarian carcinomas (HGSC) from The Cancer Genome Atlas (TCGA) were evaluated independently for association between FOLR1 mRNA upregulation and survival.</p><p>Results: FOLR1 expression ranged from 76% in HGSC to 11% in mucinous carcinomas in OTTA. For HGSC, the association between FOLR1 expression and OS changed significantly during the years following diagnosis in OTTA (P interaction ¼ 0.01, N ¼ 1422) and TCGA (P interaction ¼ 0.01, N ¼ 485). In OTTA, particularly for FIGO stage I/II tumours, patients with FOLR1-positive HGSC showed increased OS during the first 2 years only (hazard ratio ¼ 0.44, 95% confidence interval ¼ 0.20-0.96) and patients with FOLR1-positive clear cell carcinomas (CCC) showed decreased PFS independent of follow-up time (HR ¼ 1.89, 95% CI ¼ 1. <ref type="bibr">10-3.25, N ¼ 259)</ref>. In TCGA, FOLR1 mRNA upregulation in HGSC was also associated with increased OS during the first 2 years following diagnosis irrespective of tumour stage (HR: 0.48, 95% CI: 0.25-0.94).</p><p>Conclusions: FOLR1-positive HGSC tumours were associated with an increased OS in the first 2 years following diagnosis. Patients with FOLR1-negative, poor prognosis HGSC would be unlikely to benefit from anti-FOLR1 therapies. In contrast, a decreased PFS interval was observed for FOLR1-positive CCC. The clinical efficacy of FOLR1-targeted interventions should therefore be evaluated according to histology, stage and time following diagnosis.</p><p>Folate receptor 1 (FOLR1) is a member of the folate receptor family that has restricted expression in normal epithelial cells, but is reported to be highly expressed in various tumours of epithelial origin including the majority of ovarian carcinomas <ref type="bibr" target="#b20">(Kelemen et al, 2005;</ref><ref type="bibr" target="#b35">Parker et al, 2005;</ref><ref type="bibr" target="#b5">Chen et al, 2012;</ref><ref type="bibr" target="#b6">Crane et al, 2012;</ref><ref type="bibr" target="#b8">Despierre et al, 2013;</ref><ref type="bibr" target="#b34">O'Shannessy et al, 2013)</ref>. FOLR1 has high affinity for binding folic acid <ref type="bibr" target="#b35">(Parker et al, 2005)</ref>. Because folate is essential for DNA synthesis and one-carbon transfer, it has been hypothesised that FOLR1 might confer a growth advantage to the tumour by modulating folate uptake <ref type="bibr" target="#b17">(Kane et al, 1988)</ref> or generating regulatory signals <ref type="bibr" target="#b31">(Miotti et al, 2000)</ref>. However, others showed that FOLR1 was not the major transport route for intracellular accumulation of physiological folates or anti-folates in various cell lines including the IGROV-1 ovarian cancer cells <ref type="bibr" target="#b16">(Kamen and Smith, 2012)</ref>, thereby disputing the theory of FOLR1medicated tumour uptake of folate for proliferation.</p><p>Studies evaluating the prognostic value of FOLR1 expression in ovarian carcinoma have produced conflicting results. <ref type="bibr" target="#b5">Chen et al (2012)</ref> reported that FOLR1 mRNA upregulation was an unfavourable prognostic marker in a study of 91 serous ovarian carcinomas. In two studies that used immunohistochemistry (IHC), women with FOLR1 expressing ovarian carcinomas had no difference in survival rate: RR 0.86, 95% CI 0.57-1.31, P ¼ 0.49, N ¼ 186 <ref type="bibr" target="#b15">(Kalli et al, 2008)</ref> and RR 0.80, 95% CI 0.5-1.1, P ¼ 0.2, N ¼ 361 <ref type="bibr" target="#b6">(Crane et al, 2012)</ref>. These two studies contained a mixture of all histological types, which may mask associations when both the marker prevalence <ref type="bibr" target="#b15">(Kalli et al, 2008)</ref> and survival rates <ref type="bibr" target="#b22">(Kobel et al, 2008)</ref> differ between the histological types.</p><p>The prognostic significance of FOLR1 may have therapeutic relevance. FOLR1 selectivity, affinity and restricted tissue distribution has christened it as a universal target for exploitation <ref type="bibr" target="#b45">(van Dam et al, 2011)</ref> for therapy or imaging of solid tumours <ref type="bibr" target="#b27">(Leamon and Reddy, 2004)</ref> or circulating tumour cells <ref type="bibr" target="#b12">(He et al, 2008)</ref>. Different treatment modalities have been proposed including folic acid-conjugated toxins that bind FOLR1 and release the toxin upon internalisation to kill tumour cells <ref type="bibr" target="#b18">(Kelemen, 2006)</ref>, and antitumour immune-based therapies that enhance the body's natural immunity against tumour cells <ref type="bibr" target="#b21">(Knutson et al, 2006)</ref>. However, clinical trials testing therapies against FOLR1 in ovarian carcinoma have produced mixed results. For example, farletuzumab <ref type="bibr" target="#b26">(Konner et al, 2010;</ref><ref type="bibr" target="#b43">Spannuth et al, 2010;</ref><ref type="bibr" target="#b1">Armstrong et al, 2013)</ref> is a humanised monoclonal antibody against FOLR1, which was shown to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and to inhibit cell growth of a Chinese hamster ovary cell line transfected with FOLR1 when grown in low-folate medium <ref type="bibr" target="#b9">(Ebel et al, 2007)</ref>, although subsequent studies showed it minimally altered cell growth in cell lines naturally expressing FOLR1, including IGROV-1 ovarian cancer cells <ref type="bibr" target="#b16">(Kamen and Smith, 2012)</ref>. The results from a phase III clinical trial (NCT00849667) found that farletuzumab in combination with carboplatin and taxane did not meet the study's primary end point of progression-free survival (PFS), and analyses are ongoing in patient subsets <ref type="bibr" target="#b47">(Walters et al, 2013)</ref>. More recently, a phase II clinical trial reported longer median PFS among 100 selected patients with recurrent platinum-resistant ovarian carcinoma who were treated with a combination of vintafolide, a folic acid-desacetylvinblastine conjugate that binds to the folate receptor, and pegylated liposomal doxorubicin (PLD) compared with 49 patients who received PLD alone (5.0 vs 2.7 months PFS, respectively; P ¼ 0.03) <ref type="bibr" target="#b33">(Naumann et al, 2013)</ref>. The drug was particularly effective in patients diffusely positive for FOLR1. No difference in overall survival (OS) was detected, although the trial was not powered to detect a statistical difference <ref type="bibr" target="#b33">(Naumann et al, 2013)</ref>.</p><p>To address discrepant findings and to improve upon previous study designs, we evaluated tumours from 2801 patients from the Ovarian Tumour Tissue Analysis (OTTA) consortium to assess the prevalence of FOLR1 protein expression and to associate prevalence with survival for the different histological types separately. The goal of the OTTA consortium is to combine tissue microarray resources to overcome the limitations of prognostic studies associated with small sample sizes. We also utilised data from The Cancer Genome Atlas (TCGA) as a large, independent sample to evaluate these associations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head><p>Patients. Twelve individual studies comprising 2801 patients participating in the OTTA consortium were included for FOLR1 IHC expression analysis. Several of these studies also participated in previous OTTA IHC analyses <ref type="bibr" target="#b23">(Kobel et al, 2013;</ref><ref type="bibr" target="#b40">Sieh et al, 2013)</ref> and were assessed using a biomarker-assisted review of patients' slides for histological classification <ref type="bibr" target="#b23">(Kobel et al, 2013)</ref>. Informed consent was obtained from patients in seven of 12 studies. For the Alberta Ovarian Tumor Types study (AOV), Calgary Serous Carcinoma study (CAL), Nottingham Ovarian Cancer study (NOT), Toronto Ovarian Cancer study (TOC) and British Columbia Cancer Agency study (VAN), the institutional research ethics boards waived the need to obtain consent and all local human research investigations committees approved each study. Key demographical and clinical data on the patients were merged into one common data set that was checked for consistency and completeness, and discrepancies were addressed with individual study investigators.</p><p>Immunohistochemistry (IHC). Centralised IHC was performed on a Leica Bond Max platform (Leica Microsystems, Wetzlar, Germany). The submitted glass slides from tissue microarrays were subjected to heat-induced antigen retrieval for 20 min using the Leica Epitope Retrieval Solution 2. Slides were incubated with the FOLR1 mouse monoclonal antibody from Novocastra (Leica Microsystems) clone BN3.2 (catalogue #NCL-F-FRalpha) for 15 min at a 1 : 50 dilution.</p><p>Scoring. Two observers (MK, JM) scored the FOLR1 staining. We combined a measure of the intensity, extent and subcellular localisation into a five-tier scoring system: absent or weak staining, strong staining of 1-50% of tumour cells irrespective of subcellular localisation, strong staining of 450% of tumour cells with membranous localisation (with no penalisation for accompanying weak cytoplasmic staining), strong staining of 50-95% of tumour cells with cytoplasmic staining (and membranous staining still present) and strong staining of 495% of tumour cells with cytoplasmic staining <ref type="figure" target="#fig_0">(Figure 1</ref>). The inter-observer reproducibility of the five-tier IHC scoring system between the two observers was evaluated in a subset of 183 patients and was high (weighted Cohen's kappa ¼ 0.91). We also compared the five-tier IHC scores for FOLR1 obtained using the BN3.2 antibody with FOLR1 mRNA expression data derived by RNA sequencing from a subset of 36 patients <ref type="bibr" target="#b39">(Shah et al, 2009)</ref>. The IHC scores correlated reasonably well with the mRNA expression values (Pearson r ¼ 0.77).</p><p>The Cancer Genome Atlas (TCGA). We downloaded publiclyavailable data from 563 serous ovarian carcinomas from TCGA (The Cancer Genome Atlas Research Network, 2011) using the cBIOPortal for Cancer Genomics <ref type="bibr" target="#b4">(Cerami et al, 2012)</ref> to assess prevalence of FOLR1 mRNA expression in tumour relative to normal tissue (fallopian tube) and to evaluate expression with survival outcomes as described below. Gene expression in TCGA was evaluated using the Agilent 244K Custom Gene Expression G4502A_07 (Santa Clara, CA, USA) assayed at the University of North Carolina and expressed as fold change between tumour and normal tissue on the log2 scale (The Cancer Genome Atlas Research Network, 2011).</p><p>Statistical analysis. We assessed 2801 patients from the OTTA consortium for prevalence of FOLR1 expression and included the five main histological types: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), mucinous carcinoma (MC), endometrioid carcinoma (EC) and clear cell carcinoma (CCC). Patients with absent or weak FOLR1 staining were recorded as negative, whereas all the other FOLR1 staining patterns were considered positive results. In separate analyses using the larger sample size of HGSC in OTTA, we visually inspected Kaplan-Meier survival curves and evaluated statistical associations between patients using the five-tier scoring system for FOLR1 and also with different combinations of scores (e.g., strong staining of 450% of tumour cells with cytoplasmic or membranous staining vs all other staining patterns) stratified by the FIGO (International Federation of Obstetricians and Gynaecologists) stage. None of these alternate combinations produced associations that were materially different from the positive/ negative staining comparison (data not shown).</p><p>The Cox proportional hazard model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) between positive/negative categories of FOLR1 and OS or PFS stratified by histological type. In the OTTA consortium, OS was defined as death from any cause after ovarian carcinoma diagnosis and PFS was defined as survival without disease progression or recurrence determined by radiological, serological or clinical evidence or death from any cause, whichever came first. Stage at diagnosis was determined using the cancer registry and/or FIGO stage information from each site (SEER guidelines: http://seer.cancer.gov/) and categorised as FIGO stage I/II (localised and regional) and FIGO stage III/IV (distant). Because time from diagnosis to study entry was variable, we allowed for left truncation with time at risk starting on the date of diagnosis and time under observation beginning at the time of study entry. Analyses were right censored at 5 years after ovarian carcinoma diagnosis in order to reduce the number of non-ovarian carcinoma-related deaths. The proportional hazard assumption was evaluated with standard diagnostic methods, including likelihood ratio tests comparing models with and without terms that modelled covariates as a function of followup time on the natural logarithmic scale <ref type="bibr" target="#b14">(Hosmer and Lameshow, 1999)</ref>. Final models were fitted using Cox regression stratified by study to correct for violations of the proportional hazard assumption and adjusted for potential confounding with age at diagnosis (o70 or X70 years), FIGO tumour stage (I/II, III/IV or missing) and presence of residual disease at primary surgery (macroscopic, no macroscopic or missing). An interaction term between the aforementioned covariates and follow-up time was included, where necessary, to improve model fit. In addition, we considered models separately by the FIGO tumour stage. Data for regression analyses were available for 2636 patients following the exclusion of patients with missing vital status (N ¼ 13), missing time from diagnosis to study entry (N ¼ 66), missing follow-up time (N ¼ 43), missing FIGO stage (N ¼ 84, excluded for stagestratified analyses only) and patients with study entry 45 years from diagnosis (N ¼ 43).</p><p>Using TCGA data, FOLR1 mRNA information was available for 485 patients and we defined mRNA upregulation as 41 s.d. from the mean on the log2 scale. Associations with OS and PFS were evaluated with follow-up time as described above and adjusted for the FIGO tumour stage (I/II, III/IV or missing) and presence of residual disease at primary surgery (macroscopic, no macroscopic or missing). Separate models also adjusted for platinum therapy sensitivity (resistant, sensitive, too early or missing) and treatment response (complete response, partial response, progressive disease, stable disease or missing). Age at diagnosis was not available in TCGA.</p><p>Statistical tests were two sided and were implemented with SAS (version 9.1, SAS Institute, Cary, NC, USA) and Stata/SE (version 13.1, StataCorp, College Station, TX, USA). The study followed the REMARK guidelines <ref type="bibr" target="#b29">(McShane et al, 2005)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>Study and patient characteristics. <ref type="table" target="#tab_0">Table 1</ref> describes the participating studies and methods of patient ascertainment and histological review. <ref type="table" target="#tab_1">Table 2</ref> lists the 2801 women with ovarian carcinoma that were included in the FOLR1 expression prevalence analysis, stratified by study and histological type. As expected, women with HGSC were older, were diagnosed with high tumour stage and were more likely to have macroscopic residual disease and shorter OS and PFS compared with women with EC <ref type="table" target="#tab_2">(Table 3)</ref>. Women with EC had the best prognosis.</p><p>FOLR1 expression across histological types. We observed differences in FOLR1 expression by histological type: patients with tumours of LGSC, MC, EC or CCC histology were more likely to have absent or weak FOLR1 staining compared with patients with HGSC tumours <ref type="table" target="#tab_2">(Table 3)</ref>. FOLR1-positive expression was seen in 1149 out of 1507 patients (76.2%) with HGSC, 45 out of 91 patients (49.5%) with LGSC and 141 out of 446 patients (31.6%) with CCC. Normal fallopian tube tissue was included as a control on the tissue microarrays and was FOLR1-positive in 8 out of 8 samples (100%) <ref type="figure" target="#fig_0">(Figure 1</ref>).</p><p>Association between FOLR1 expression in HGSC tumours and survival. In OTTA, there were no statistically significant associations with OS or PFS for HGSC overall or when evaluated separately by the FIGO stage; however, the association between FOLR1 expression and OS changed when stratified by follow-up period (P interaction with time ¼ 0.01) <ref type="table" target="#tab_3">(Table 4</ref>). FOLR1 expression was associated with a 29% non-significant increased OS (P ¼ 0.08) during the first year following diagnosis and a 50% non-significant decreased OS during the fourth year. The pattern of changing survival with increasing follow-up time, however, was most evident among patients with FIGO stage I/II tumours (P interaction with time ¼ 0.02). Among these patients, FOLR1 expression was associated with a 56% significant increased OS during the first 2 years of follow-up only (HR: 0.44, 95% CI: 0.20-0.96, P ¼ 0.04). An interaction between FOLR1 expression and follow-up time was not observed with PFS.</p><p>Among 485 patients with HGSC in TCGA, FOLR1 mRNA upregulation was present in 93 patients <ref type="bibr">(19%)</ref>. The associations between FOLR1 mRNA upregulation and survival in TCGA were similar to those observed in the OTTA data for HGSC. A significant interaction with follow-up time was seen for OS (P interaction with time ¼ 0.02) ( <ref type="table" target="#tab_4">Table 5</ref>). Following additional adjustment for platinum sensitivity and treatment response, FOLR1 mRNA upregulation was associated with a 52% significant increased OS during the first 2 years of follow-up only (HR: 0.48, 95% CI: 0.25-0.94, P ¼ 0.03) ( <ref type="table" target="#tab_4">Table 5)</ref>. Although most of these patients had FIGO stage III/IV tumours, the association did not strengthen when restricted to advanced stage tumours (P ¼ 0.05). A non-significant interaction between FOLR1 mRNA upregulation and follow-up time was observed for PFS.</p><p>Association between FOLR1 expression in non-HGSC tumours and survival in OTTA. No significant interactions were found between FOLR1 expression and follow-up time for the other ovarian histological types. When stratified by stage, a nonsignificant decreased OS interval was observed among patients with CCC and FIGO stage I/II (HR: 1.62, 95% CI: 0.97-2.71, P ¼ 0.07) <ref type="table" target="#tab_5">(Table 6</ref>), whereas a 57% significant decreased PFS interval was seen among patients with CCC overall (HR: 1.57, 95% CI: 1.06-2.34, P ¼ 0.02), which was more pronounced among patients with FIGO stage I/II tumours (HR: 1.89, 95% CI: 1.10-3.25, P ¼ 0.02) ( <ref type="table" target="#tab_6">Table 7)</ref>. No other associations were found.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>Our investigation showed that the association between FOLR1 expression or FOLR1 mRNA upregulation among B1900 patients with HGSC from two independent data sets changed significantly during the years following diagnosis. In OTTA, this translated to an increase in OS by 56% among women with FOLR1-positive HGSC in the first 2 years of follow-up only and a decrease in PFS by 89% among women with FOLR1-positive CCC irrespective of follow-up time. Both findings were more pronounced among patients with FIGO stage I/II tumours. Both our OTTA data and those we analysed from TCGA provide evidence, for the first time, that the association between FOLR1 expression and OS in HGSC changes with the duration of follow-up regardless of whether FOLR1 was measured as protein or mRNA. Previous studies reported either unfavourable prognosis    All models except FIGO stage I/II model additionally adjusted for platinum sensitivity (resistant, sensitive, too early or missing) and treatment response (complete response, partial response, progressive disease, stable disease or missing). <ref type="bibr" target="#b5">(Chen et al, 2012)</ref> or no adverse association <ref type="bibr" target="#b15">(Kalli et al, 2008;</ref><ref type="bibr" target="#b6">Crane et al, 2012)</ref> between FOLR1 protein or mRNA and OS. Time following diagnosis in those studies ranged from B6.5 years <ref type="bibr" target="#b5">(Chen et al, 2012)</ref> to 15 years <ref type="bibr" target="#b15">(Kalli et al, 2008)</ref> and an average of the HR would obscure the modifying effect of follow-up time, as observed in the current investigation when we did not stratify by follow-up time. The change in association between FOLR1 expression and OS was more evident among FIGO stage I/II tumours in OTTA, whereas TCGA was composed mainly of FIGO stage III/IV tumours. For HGSC that did not express FOLR1, patients were observed to have an increased rate of death within 2 years after diagnosis, which attenuated with follow-up time. We speculated whether the absence of FOLR1 expression in the primary HGSC tumour was an indicator of tumours that responded poorly to standard platinum chemotherapy. Inclusion of treatment response indicators in statistical models that were available in the TCGA data analysis, however, did not weaken the associations with OS and did not support this hypothesis. Although it is possible that FOLR1 expression itself may have changed with follow-up time to explain our observations, this is not supported by studies that showed no significant change in FOLR1 expression following chemotherapy in patients with HGSC-matched tumour from primary surgery and either interval debulking surgery or surgery for recurrent disease <ref type="bibr" target="#b6">(Crane et al, 2012;</ref><ref type="bibr" target="#b8">Despierre et al, 2013)</ref>. It is possible, therefore, that differences between patients with FOLR1negative poor-prognosis HGSC and FOLR1-positive tumours, which showed a survival advantage, may be from differences in intrinsic tumour biology.  The association between FOLR1 protein expression and decrease in PFS interval in patients with CCC and, specifically FIGO stage I/II tumours, is potentially interesting and will require independent confirmation. FIGO stage I/II tumours comprise the majority of CCC (almost 80% of CCC and 12% of all patients in our study) and their optimal management represents a clinical dilemma, because B20% of patients relapse and are resistant to platinum-based chemotherapy <ref type="bibr" target="#b24">(Kobel et al, 2010a;</ref><ref type="bibr" target="#b0">Anglesio et al, 2011)</ref>. Existing clinical trials that are testing therapies to FOLR1 expression in ovarian carcinoma are comprised mostly of HGSC and one reported a favourable outcome among patients with platinum-resistant recurrent ovarian carcinoma <ref type="bibr" target="#b33">(Naumann et al, 2013)</ref>, which is a clinical profile similar to CCC. Interestingly, that study <ref type="bibr" target="#b33">(Naumann et al, 2013)</ref> included eight patients with CCC (seven in the vintafolide arm). It remains to be evaluated whether targeting therapies specifically to FOLR1 in patients with CCC and FIGO stage I/II tumours improves their survival.</p><p>We observed that FOLR1 protein was expressed in 76% of HGSC, which agrees with a recent estimate of prevalence by <ref type="bibr" target="#b6">Crane et al (2012)</ref> of 82% among 210 patients with HGSC. Further, only B30% of CCC and EC, and 11% of MC were positive for FOLR1. These estimates are lower than those reported previously and may be from the much smaller sample sizes evaluated in studies of HGSC (N ¼ 36-73) <ref type="bibr" target="#b20">(Kelemen et al, 2005;</ref><ref type="bibr" target="#b8">Despierre et al, 2013;</ref><ref type="bibr" target="#b34">O'Shannessy et al, 2013)</ref> and of other histological types <ref type="bibr" target="#b15">(Kalli et al, 2008;</ref><ref type="bibr" target="#b6">Crane et al, 2012)</ref>. We also observed FOLR1 expression in normal fallopian tube tissue samples, which is increasingly accepted as the cell of origin for most HGSC <ref type="bibr" target="#b36">(Piek et al, 2001;</ref><ref type="bibr" target="#b7">Crum et al, 2007)</ref>. Others also reported strong FOLR1 expression in normal fallopian tube <ref type="bibr" target="#b46">(Veggian et al, 1989;</ref><ref type="bibr" target="#b34">O'Shannessy et al, 2013)</ref>, postulating that FOLR1 tumour expression is maintained from cell type-oforigin (O'Shannessy et al, 2013). However, at least two previous studies found strong FOLR1 expression in normal ovarian surface epithelium <ref type="bibr" target="#b49">(Wu et al, 1999;</ref><ref type="bibr" target="#b20">Kelemen et al, 2005)</ref>, including one that prospectively collected ovarian surface epithelial samples from healthy postmenopausal women undergoing oophorectomy <ref type="bibr" target="#b20">(Kelemen et al, 2005)</ref>. Given the difficulty to obtain viable normal ovarian surface epithelium, we question whether earlier studies <ref type="bibr" target="#b46">(Veggian et al, 1989;</ref><ref type="bibr" target="#b38">Ross et al, 1994;</ref><ref type="bibr" target="#b35">Parker et al, 2005)</ref> found low expression in ovarian stroma rather than epithelium.</p><p>There are several strengths to this investigation. We showed the novel result that the association between FOLR1 expression and OS changes with the duration of follow-up and with histological cell type. Our evaluation is the largest assembly of an unselected sample of HGSC and other ovarian carcinoma types. We performed a centralised IHC assay with excellent inter-observer reproducibility that correlated reasonably well with FOLR1 mRNA expression level among a subset of patients in our sample. Harmonisation of clinical variables contributed to robust statistical analysis and control for potential confounding. We also leveraged TCGA data to evaluate the association with HGSC in an independent data set and, although the direction and magnitude of the associations were similar between OTTA and TCGA samples, TCGA had too few tumours with FIGO stage I/II to evaluate.</p><p>In summary, we found that FOLR1 protein was widely expressed in patients with HGSC in OTTA and that expression was associated with increased OS in the first 2 years following diagnosis. The association with clinical outcome in CCC was opposite to that seen for HGSC with a decreased progression-free interval observed for FOLR1-positive CCC. Both findings were more pronounced among patients with FIGO stage I/II tumours. Our study highlights the need to evaluate FOLR1-targeted therapy outcomes by histological type, stage and time following diagnosis if FOLR1 is to be used as a target for therapeutic intervention.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Immunohistochemical staining of FOLR1. (A) No staining in a mucinous carcinoma. (B) Strong staining of 1-50% of tumour cells in a high-grade serous carcinoma. (C) Strong staining of 450% of tumour cells with predominant membranous localisation in a high-grade serous carcinoma. (D) Strong staining of 50-90% of tumour cells with cytoplasmic staining (and membranous staining still present) in a highgrade serous carcinoma. (E) Strong staining of 490% of tumour cells with cytoplasmic staining in a high-grade serous carcinoma. (F) Strong staining of 450% of epithelial cells with predominant membranous localisation in normal fallopian tube.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Description of 12 participating studies in OTTA</figDesc><table><row><cell></cell><cell>Study</cell><cell>Study</cell><cell>Recruitment</cell><cell>Ascertainment of patients and</cell><cell></cell></row><row><cell>Study</cell><cell>abbreviation</cell><cell>location</cell><cell>period</cell><cell>clinical data</cell><cell>Pathology data and review</cell></row><row><cell>Australian Ovarian Cancer</cell><cell>AOC</cell><cell>Australia</cell><cell>2002-2006</cell><cell>Treatment centers throughout Australia;</cell><cell>Pathology reports and</cell></row><row><cell>Study (Merritt et al, 2008)</cell><cell></cell><cell></cell><cell></cell><cell>cancer registries serving Queensland,</cell><cell>diagnostic slides reviewed by</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>South and Western Australia; longitudinal</cell><cell>a panel of gynaecologic</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>follow-up through regular review of</cell><cell>pathologists</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>medical records</cell><cell></cell></row><row><cell>Alberta Ovarian Tumor</cell><cell>AOV</cell><cell>Alberta,</cell><cell>1998-2009</cell><cell>Population-based Alberta Cancer</cell><cell>Pathology reports and</cell></row><row><cell>Types Study (Kelemen</cell><cell></cell><cell>Canada</cell><cell></cell><cell>Registry. Annual updates are performed</cell><cell>histological slides reviewed by</cell></row><row><cell>et al, 2013)</cell><cell></cell><cell></cell><cell></cell><cell>for vital statistics</cell><cell>gynaecologic pathologist</cell></row><row><cell>Bavarian Ovarian Cancer</cell><cell>BAV</cell><cell>Southeast</cell><cell>2002-2006</cell><cell>Gynecologic Oncology Center at the</cell><cell>Centralised review of</cell></row><row><cell>Study (Hein et al, 2013)</cell><cell></cell><cell>Germany</cell><cell></cell><cell>Comprehensive Cancer Center</cell><cell>pathology reports and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Erlangen-Nuremberg</cell><cell>histological slides for all cases</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>by study pathologists</cell></row><row><cell>Calgary Serous Carcinoma</cell><cell>CAL</cell><cell>Calgary,</cell><cell>2003-2007</cell><cell>Hospital-based retrospective</cell><cell>Histological review of all slides</cell></row><row><cell>Study (Bromley et al, 2012)</cell><cell></cell><cell>Canada</cell><cell></cell><cell>observational study</cell><cell>by study pathologist</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>supported by centralised</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>biomarker analysis</cell></row><row><cell>Novel risk factors and</cell><cell>HOP</cell><cell>Western PA,</cell><cell>2003-2009</cell><cell>Hospital registries and active surveillance</cell><cell>Medical chart review for</cell></row><row><cell>potential early detection</cell><cell></cell><cell>Northeastern</cell><cell></cell><cell>of medical practices in three catchment</cell><cell>all cases</cell></row><row><cell>markers for the Ovarian</cell><cell></cell><cell>Ohio,</cell><cell></cell><cell>areas</cell><cell></cell></row><row><cell>Cancer Study (Lo-Ciganic</cell><cell></cell><cell>Western NY,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>et al, 2012)</cell><cell></cell><cell>USA</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Malignant Ovarian Cancer</cell><cell>MAL</cell><cell>Denmark</cell><cell>1994-1999</cell><cell>Gynecological departments in</cell><cell>Pathology reports reviewed</cell></row><row><cell>Study (Glud et al, 2004;</cell><cell></cell><cell></cell><cell></cell><cell>Copenhagen, Frederiksberg and seven</cell><cell>for all cases and histological</cell></row><row><cell>Soegaard et al, 2007)</cell><cell></cell><cell></cell><cell></cell><cell>surrounding counties</cell><cell>slides reviewed for 30% by</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>gynaecologic pathologist</cell></row><row><cell>Mayo Clinic Ovarian</cell><cell>MAY þ MAC</cell><cell>Northcentral</cell><cell>2000-2009</cell><cell>Mayo Clinic medical records and State</cell><cell>Review by Mayo Clinic</cell></row><row><cell>Cancer Study (Goode et al,</cell><cell></cell><cell>USA</cell><cell></cell><cell>death certificates</cell><cell>gynaecologic pathologists</cell></row><row><cell>2011)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>supported by centralised</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>biomarker analysis</cell></row><row><cell>Nottingham Study</cell><cell>NOT</cell><cell>UK</cell><cell>1991-2008</cell><cell cols="2">Hospital records and Trent cancer registry Pathology reports reviewed by</cell></row><row><cell>(Williams et al, 2012)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>gynaecologic pathologist</cell></row><row><cell>Study of Epidemiology and</cell><cell>SEA</cell><cell>East Anglia</cell><cell>1998-2008</cell><cell>East Anglia and West Midlands Cancer</cell><cell>Centralised review of</cell></row><row><cell>Risk Factors in Cancer</cell><cell></cell><cell>and West</cell><cell></cell><cell>Registry</cell><cell>pathology reports by a</cell></row><row><cell>Heredity (Song et al, 2006)</cell><cell></cell><cell>Midlands, UK</cell><cell></cell><cell></cell><cell>pathologist</cell></row><row><cell>Toronto Ovarian Cancer</cell><cell>TOC</cell><cell>Ontario,</cell><cell>1995-2003</cell><cell>Ontario Cancer Registry</cell><cell>Pathology reports and</cell></row><row><cell>Study (Narod et al, 1998)</cell><cell></cell><cell>Canada</cell><cell></cell><cell></cell><cell>histological slides reviewed by</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>a study pathologist</cell></row><row><cell>United Kingdom Ovarian</cell><cell>UKO</cell><cell>England,</cell><cell>2006-2010</cell><cell>10 major Gynecologic Oncology NHS</cell><cell>Centralised review of</cell></row><row><cell>Cancer Population Study</cell><cell></cell><cell>Wales and</cell><cell></cell><cell>centers in England, Wales and Northern</cell><cell>pathology reports by a</cell></row><row><cell>(Balogun et al, 2011)</cell><cell></cell><cell>Northern</cell><cell></cell><cell>Ireland; cancer registries; NHS Information</cell><cell>gynaecologic oncologist</cell></row><row><cell></cell><cell></cell><cell>Ireland, UK</cell><cell></cell><cell>Centre for Health and Social Care</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(England and Wales) and Central Services</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Agency (Northern Ireland)</cell><cell></cell></row><row><cell>Vancouver Ovarian Cancer</cell><cell>VAN</cell><cell>British</cell><cell>1984-2000</cell><cell>Ovarian Cancer Registry serving British</cell><cell>Histological review of all slides</cell></row><row><cell>Study (Prentice et al, 2007;</cell><cell></cell><cell>Columbia,</cell><cell></cell><cell>Columbia, and the Cheryl Brown</cell><cell>by University of British</cell></row><row><cell>Kobel et al, 2010b)</cell><cell></cell><cell>Canada</cell><cell></cell><cell>Outcomes unit</cell><cell>Columbia pathologists</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>supported by centralised</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>biomarker analysis</cell></row></table><note>Abbreviation: OTTA ¼ ovarian tumour tissue analysis.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc>Number of patients with invasive ovarian carcinoma across studies and by histological type in OTTA Abbreviations: CCC ¼ clear cell carcinoma; EC ¼ endometrioid carcinoma; HGSC ¼ high-grade serous carcinoma; LGSC ¼ low-grade serous carcinoma; MC ¼ mucinous carcinoma; OTTA ¼ ovarian tumour tissue analysis.</figDesc><table><row><cell>Study</cell><cell>Total patients</cell><cell>HGSC</cell><cell>LGSC</cell><cell>MC</cell><cell>EC</cell><cell>CCC</cell></row><row><cell>abbreviation</cell><cell>N ¼ 2801</cell><cell>N ¼ 1507</cell><cell>N ¼ 91</cell><cell>N ¼ 193</cell><cell>N ¼ 564</cell><cell>N ¼ 446</cell></row><row><cell>AOC</cell><cell>89</cell><cell>89</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>AOV</cell><cell>209</cell><cell>0</cell><cell>0</cell><cell>18</cell><cell>95</cell><cell>96</cell></row><row><cell>BAV</cell><cell>214</cell><cell>133</cell><cell>19</cell><cell>19</cell><cell>26</cell><cell>17</cell></row><row><cell>CAL</cell><cell>68</cell><cell>63</cell><cell>5</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>HOP</cell><cell>34</cell><cell>25</cell><cell>1</cell><cell>0</cell><cell>7</cell><cell>1</cell></row><row><cell>MAL</cell><cell>245</cell><cell>117</cell><cell>12</cell><cell>21</cell><cell>66</cell><cell>29</cell></row><row><cell>MAY</cell><cell>460</cell><cell>337</cell><cell>17</cell><cell>14</cell><cell>63</cell><cell>29</cell></row><row><cell>NOT</cell><cell>196</cell><cell>106</cell><cell>9</cell><cell>16</cell><cell>39</cell><cell>26</cell></row><row><cell>SEA</cell><cell>364</cell><cell>164</cell><cell>8</cell><cell>42</cell><cell>92</cell><cell>58</cell></row><row><cell>TOC</cell><cell>160</cell><cell>50</cell><cell>0</cell><cell>20</cell><cell>45</cell><cell>45</cell></row><row><cell>UKO</cell><cell>102</cell><cell>68</cell><cell>7</cell><cell>5</cell><cell>7</cell><cell>15</cell></row><row><cell>VAN</cell><cell>660</cell><cell>355</cell><cell>13</cell><cell>38</cell><cell>124</cell><cell>130</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc>Characteristics of patients with invasive ovarian carcinoma by histological type in OTTA Abbreviations: CCC ¼ clear cell carcinoma; EC ¼ endometrioid carcinoma; FOLR1 ¼ folate receptor 1; HGSC ¼ high-grade serous carcinoma; LGSC ¼ low-grade serous carcinoma; MC ¼ mucinous carcinoma; OS ¼ overall survival; OTTA ¼ ovarian tumour tissue analysis; PFS ¼ progression-free survival.Mean years follow-up among cases regardless of vital status or progression status.Smaller sample size is based on availability of OS and PFS information from patients(1422 HGSC, 85  LGSC, 178 MC, 526 EC and 425 CCC).</figDesc><table><row><cell></cell><cell>HGSC</cell><cell>LGSC</cell><cell>MC</cell><cell>EC</cell><cell>CCC</cell></row><row><cell>Characteristic</cell><cell>N ¼ 1507</cell><cell>N ¼ 91</cell><cell>N ¼ 193</cell><cell>N ¼ 564</cell><cell>N ¼ 446</cell></row><row><cell>Age at diagnosis, mean±s.d.</cell><cell>61.1±11.2</cell><cell>55.3±13.5</cell><cell>55.5±13.9</cell><cell>56.1±11.8</cell><cell>57.4±11.5</cell></row><row><cell>Total years followed a,b , mean ± s.d.</cell><cell>4.1 ± 3.2</cell><cell>5.8 ± 4.1</cell><cell>5.9 ± 4.5</cell><cell>6.9 ± 4.4</cell><cell>5.9 ± 4.6</cell></row><row><cell>Overall time to death b , years, mean±s.d.</cell><cell>3.2±2.3</cell><cell>4.3±3.1</cell><cell>2.6±2.5</cell><cell>5.0±3.9</cell><cell>3.5±3.2</cell></row><row><cell>Vital status b , N (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alive</cell><cell>421 (29.6)</cell><cell>41 (48.2)</cell><cell>114 (64.0)</cell><cell>371 (70.5)</cell><cell>239 (56.2)</cell></row><row><cell>Died</cell><cell>1001 (70.4)</cell><cell>44 (51.8)</cell><cell>64 (36.0)</cell><cell>155 (29.5)</cell><cell>186 (43.8)</cell></row><row><cell>Overall time to progression a,b , years, mean ± s.d.</cell><cell>2.5 ± 2.7</cell><cell>3.6 ± 4.1</cell><cell>4.8 ± 4.2</cell><cell>5.9 ± 4.2</cell><cell>4.8 ± 4.5</cell></row><row><cell>Progression status b , N (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Progression-free</cell><cell>344 (30.0)</cell><cell>31 (44.9)</cell><cell>88 (71.5)</cell><cell>284 (75.3)</cell><cell>201 (58.9)</cell></row><row><cell>Progressed</cell><cell>804 (70.0)</cell><cell>38 (55.1)</cell><cell>35 (28.4)</cell><cell>93 (24.7)</cell><cell>140 (41.0)</cell></row><row><cell>Stage b , N (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FIGO IA, IB, IC, II (localised)</cell><cell>379 (26.6)</cell><cell>28 (32.9)</cell><cell>130 (73.0)</cell><cell>422 (80.2)</cell><cell>328 (77.2)</cell></row><row><cell>FIGO III, IV (distant)</cell><cell>1030 (72.4)</cell><cell>58 (65.9)</cell><cell>34 (19.1)</cell><cell>88 (16.7)</cell><cell>82 (19.3)</cell></row><row><cell>Unknown</cell><cell>13 (0.9)</cell><cell>1 (1.1)</cell><cell>14 (7.9)</cell><cell>16 (3.0)</cell><cell>15 (3.5)</cell></row><row><cell>Macroscopic residual disease b , N (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>447 (31.4)</cell><cell>43 (50.6)</cell><cell>91 (51.1)</cell><cell>327 (62.2)</cell><cell>254 (59.8)</cell></row><row><cell>Yes</cell><cell>634 (45.6)</cell><cell>24 (28.2)</cell><cell>29 (16.3)</cell><cell>49 (9.3)</cell><cell>45 (10.6)</cell></row><row><cell>Unknown</cell><cell>341 (24.0)</cell><cell>18 (21.2)</cell><cell>58 (32.6)</cell><cell>150 (28.5)</cell><cell>126 (29.6)</cell></row><row><cell>FOLR1 expression, N (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent/weak</cell><cell>358 (23.8)</cell><cell>46 (51.0)</cell><cell>171 (88.6)</cell><cell>398 (70.6)</cell><cell>305 (68.3)</cell></row><row><cell>Strong 1-50%</cell><cell>371 (24.6)</cell><cell>20 (22.0)</cell><cell>12 (6.2)</cell><cell>100 (17.7)</cell><cell>88 (19.7)</cell></row><row><cell>Strong membranous 450%</cell><cell>282 (18.7)</cell><cell>15 (16.5)</cell><cell>6 (3.1)</cell><cell>44 (7.8)</cell><cell>29 (6.5)</cell></row><row><cell>Strong cytoplasmic 50-95%</cell><cell>367 (24.4)</cell><cell>8 (8.8)</cell><cell>2 (1.0)</cell><cell>17 (3.0)</cell><cell>21 (4.7)</cell></row><row><cell>Strong cytoplasmic 495%</cell><cell>129 (8.6)</cell><cell>2 (2.2)</cell><cell>2 (1.0)</cell><cell>5 (0.9)</cell><cell>3 (0.7)</cell></row></table><note>ab</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc>Associations a between FOLR1 expression b and OS and PFS for 1422 high-grade serous ovarian carcinomas in OTTA HR and 95% CI estimated using Cox regression stratified by study and adjusted for age at diagnosis, residual disease (not macroscopic, macroscopic or missing) and FIGO stage (I/II, III/IV or missing). Models that stratified by stage did not include stage as a confounder.Positive vs negative staining, where negative is absent or weak staining and positive is all other stains.</figDesc><table><row><cell></cell><cell></cell><cell>Overall survival</cell><cell></cell><cell></cell><cell>Progression-free survival</cell><cell></cell></row><row><cell>Time period</cell><cell>Died, N</cell><cell>HR (95% CI)</cell><cell>P-value</cell><cell>Progressed, N</cell><cell>HR (95% CI)</cell><cell>P-value</cell></row><row><cell>No stratification by follow-up</cell><cell>825</cell><cell>0.99 (0.84-1.18)</cell><cell>0.95</cell><cell>732</cell><cell>0.99 (0.81-1.19)</cell><cell>0.88</cell></row><row><cell>Five-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1-year follow-up</cell><cell>134</cell><cell>0.71 (0.48-1.05)</cell><cell>0.08</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>1-2-year follow-up</cell><cell>208</cell><cell>0.90 (0.65-1.26)</cell><cell>0.55</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>2-3-year follow-up</cell><cell>207</cell><cell>1.23 (0.86-1.74)</cell><cell>0.26</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>3-4-year follow-up</cell><cell>174</cell><cell>0.93 (0.64-1.34)</cell><cell>0.69</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>4-5-year follow-up</cell><cell>102</cell><cell>1.50 (0.87-2.58)</cell><cell>0.15</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.01</cell><cell></cell><cell></cell><cell>0.84</cell><cell></cell></row><row><cell>Three-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1-year follow-up</cell><cell>134</cell><cell>0.71 (0.48-1.05)</cell><cell>0.08</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>1-4-year follow-up</cell><cell>589</cell><cell>1.01 (0.82-1.24)</cell><cell>0.91</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>4-5-year follow-up</cell><cell>102</cell><cell>1.50 (0.87-2.58)</cell><cell>0.15</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>Stratified by stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FIGO stage I/II</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No stratification by follow-up</cell><cell>126</cell><cell>1.07 (0.72-1.58)</cell><cell>0.74</cell><cell>88</cell><cell>1.04 (0.66-1.65)</cell><cell>0.84</cell></row><row><cell>Three-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-2-year follow-up</cell><cell>29</cell><cell>0.44 (0.20-0.96)</cell><cell>0.04</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>2-3-year follow-up</cell><cell>35</cell><cell>1.25 (0.58-2.69)</cell><cell>0.57</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>3-5-year follow-up</cell><cell>62</cell><cell>1.62 (0.88-2.96)</cell><cell>0.12</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.02</cell><cell></cell><cell></cell><cell>0.70</cell><cell></cell></row><row><cell>FIGO stage III/IV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No stratification by follow-up</cell><cell>692</cell><cell>1.00 (0.83-1.21)</cell><cell>0.97</cell><cell>643</cell><cell>1.01 (0.82-1.23)</cell><cell>0.95</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.21</cell><cell></cell><cell></cell><cell>0.95</cell><cell></cell></row></table><note>Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio; OS ¼ overall survival; PFS ¼ progression-free survival.ab</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5 .</head><label>5</label><figDesc>Associations between FOLR1 mRNA upregulation and OS and PFS for 485 serous ovarian carcinomas in TCGA</figDesc><table><row><cell></cell><cell></cell><cell>Overall</cell><cell></cell><cell>Overall</cell><cell></cell><cell></cell><cell>Progression-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>survival a</cell><cell></cell><cell>survival b</cell><cell></cell><cell>Progressed,</cell><cell>free survival a</cell><cell></cell></row><row><cell>Time period</cell><cell>Died, N</cell><cell>HR (95% CI)</cell><cell cols="3">P-value HR (95% CI) P-value</cell><cell>N</cell><cell>HR (95% CI)</cell><cell>P-value</cell></row><row><cell>No stratification by follow-up</cell><cell>238</cell><cell>0.78 (0.55-1.10)</cell><cell>0.15</cell><cell>0.84 (0.60-1.19)</cell><cell>0.34</cell><cell>280</cell><cell>1.08 (0.81-1.45)</cell><cell>0.59</cell></row><row><cell>Five-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1-year follow-up</cell><cell>42</cell><cell>0.31 (0.10-1.01)</cell><cell>0.05</cell><cell>0.42 (0.13-1.38)</cell><cell>0.15</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>1-2-year follow-up</cell><cell>53</cell><cell>0.57 (0.26-1.27)</cell><cell>0.17</cell><cell>0.54 (0.24-1.22)</cell><cell>0.14</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>2-3-year follow-up</cell><cell>54</cell><cell>1.26 (0.68-2.36)</cell><cell>0.74</cell><cell>1.25 (0.65-2.40)</cell><cell>0.50</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>3-4-year follow-up</cell><cell>53</cell><cell>0.96 (0.48-1.91)</cell><cell>0.91</cell><cell>1.06 (0.52-2.15)</cell><cell>0.87</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>4-5-year follow-up</cell><cell>70</cell><cell>0.81 (0.45-1.46)</cell><cell>0.48</cell><cell>0.99 (0.42-2.34)</cell><cell>0.97</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.02</cell><cell></cell><cell>0.01</cell><cell></cell><cell></cell><cell>0.33</cell><cell></cell></row><row><cell>Three-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-2-year follow-up</cell><cell>95</cell><cell>0.45 (0.23-0.87)</cell><cell>0.02</cell><cell>0.48 (0.25-0.94)</cell><cell>0.03</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>2-3-year follow-up</cell><cell>54</cell><cell>1.26 (0.68-2.36)</cell><cell>0.74</cell><cell>1.25 (0.65-2.40)</cell><cell>0.50</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>3-5-year follow-up</cell><cell>123</cell><cell>0.87 (0.56-1.37)</cell><cell>0.56</cell><cell>1.01 (0.59-1.73)</cell><cell>0.98</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>Stratified by stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FIGO stage I/II</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No stratification by follow-up</cell><cell>6</cell><cell>0.83 (0.08-8.29)</cell><cell>0.87</cell><cell>0.83 (0.08-8.29)</cell><cell>0.87</cell><cell>14</cell><cell>0.65 (0.17-2.48)</cell><cell>0.53</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.12</cell><cell></cell><cell>0.12</cell><cell></cell><cell></cell><cell>0.07</cell><cell></cell></row><row><cell>FIGO stage III/IV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No stratification by follow-up</cell><cell>230</cell><cell>0.78 (0.56-1.11)</cell><cell>0.17</cell><cell>0.85 (0.60-1.21)</cell><cell>0.37</cell><cell>266</cell><cell>1.11 (0.83-1.50)</cell><cell>0.48</cell></row><row><cell>Three-period follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-2-year follow-up</cell><cell>93</cell><cell>0.47 (0.24-0.91)</cell><cell>0.02</cell><cell>0.52 (0.27-1.01)</cell><cell>0.05</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>2-3-year follow-up</cell><cell>53</cell><cell>1.29 (0.69-2.42)</cell><cell>0.42</cell><cell>1.28 (0.67-2.45)</cell><cell>0.46</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>3-5-year follow-up</cell><cell>84</cell><cell>0.87 (0.50-1.50)</cell><cell>0.61</cell><cell>0.96 (0.55-1.67)</cell><cell>0.88</cell><cell></cell><cell>-</cell><cell>-</cell></row><row><cell>P interaction with time</cell><cell></cell><cell>0.03</cell><cell></cell><cell>0.02</cell><cell></cell><cell></cell><cell>0.51</cell><cell></cell></row></table><note>Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio; mRNA ¼ messenger RNA; OS ¼ overall survival; PFS ¼ progression-free survival; TCGA ¼ The Cancer Genome Atlas.a HR and 95% CI estimated using Cox regression adjusted for residual disease (not macroscopic, macroscopic or missing) and FIGO stage (I/II, III/IV or missing). Models that stratified by stage did not include stage as a confounder.b</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 6 .</head><label>6</label><figDesc>Associations a between FOLR1 expression and OS by ovarian carcinoma histological type in OTTA Abbreviations: CCC ¼ clear cell carcinoma; CI ¼ confidence interval; EC ¼ endometrioid carcinoma; HR ¼ hazard ratio; FOLR1 ¼ folate receptor 1; LGSC ¼ low-grade serous carcinoma; MC ¼ mucinous carcinoma; OS ¼ overall survival; OTTA ¼ ovarian tumour tissue analysis.HR and 95% CI estimated using Cox regression stratified by study and adjusted for age, residual disease (not macroscopic, macroscopic or missing) and FIGO stage (I/II, III/IV or missing). Models that stratified by stage did not include stage as a confounder.</figDesc><table><row><cell></cell><cell>LGSC</cell><cell>MC</cell><cell>EC</cell><cell>CCC</cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell></row><row><cell>Alive/died, N</cell><cell>54/31</cell><cell>125/53</cell><cell>435/91</cell><cell>281/143</cell></row><row><cell>FOLR1 expression</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>1.31 (0.56-3.07)</cell><cell>0.74 (0.26-2.12)</cell><cell>0.93 (0.57-1.51)</cell><cell>1.15 (0.80-1.64)</cell></row><row><cell>P-value</cell><cell>0.53</cell><cell>0.58</cell><cell>0.77</cell><cell>0.45</cell></row><row><cell>Stratified by stage</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FIGO stage I/II</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alive/died, N</cell><cell>26/2</cell><cell>107/23</cell><cell>379/43</cell><cell>254/73</cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>0.58 (0.03-10.2)</cell><cell>0.28 (0.04-1.71)</cell><cell>1.32 (0.64-2.71)</cell><cell>1.62 (0.97-2.71)</cell></row><row><cell>P-value</cell><cell>0.71</cell><cell>0.17</cell><cell>0.45</cell><cell>0.07</cell></row><row><cell>FIGO stage III/IV</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alive/died, N</cell><cell>27/29</cell><cell>5/29</cell><cell>41/47</cell><cell>17/65</cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>1.16 (0.44-3.02)</cell><cell>0.72 (0.18-2.96)</cell><cell>0.66 (0.33-1.32)</cell><cell>0.72 (0.41-1.28)</cell></row><row><cell>P-value</cell><cell>0.77</cell><cell>0.65</cell><cell>0.24</cell><cell>0.21</cell></row></table><note>ab Negative is absent or weak staining and positive is all other stains.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 7 .</head><label>7</label><figDesc>Associations a between FOLR1 expression and PFS by ovarian carcinoma histological type in OTTA Abbreviations: CCC ¼ clear cell carcinoma; CI ¼ confidence interval; EC ¼ endometrioid carcinoma; HR ¼ hazard ratio; FOLR1 ¼ folate receptor 1; LGSC ¼ low-grade serous carcinoma; MC ¼ mucinous carcinoma; OTTA ¼ ovarian tumour tissue analysis; PFS ¼ progression-free survival.HR and 95% CI estimated using Cox regression stratified by study and adjusted for age, residual disease (not macroscopic, macroscopic or missing) and FIGO stage (I/II, III/IV or missing). Models that stratified by stage did not include stage as a confounder.Negative is absent or weak staining and positive is all other stains.</figDesc><table><row><cell></cell><cell>LGSC</cell><cell>MC</cell><cell>EC</cell><cell>CCC</cell></row><row><cell></cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell><cell>HR (95% CI)</cell></row><row><cell>Progression-free/progressed, N</cell><cell>32/38</cell><cell>94/28</cell><cell>301/77</cell><cell>210/123</cell></row><row><cell>FOLR1 expression</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>1.14 (0.53-2.44)</cell><cell>1.10 (0.26-4.74)</cell><cell>1.02 (0.61-1.69)</cell><cell>1.57 (1.06-2.34)</cell></row><row><cell>P-value</cell><cell>0.74</cell><cell>0.89</cell><cell>0.94</cell><cell>0.02</cell></row><row><cell>Stratified by stage</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FIGO stage I/II</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Progression-free/progressed, N</cell><cell>14/3</cell><cell>86/12</cell><cell>271/34</cell><cell>191/68</cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>Not estimable</cell><cell>2.10 (0.21-20.5)</cell><cell>1.81 (0.82-3.99)</cell><cell>1.89 (1.10-3.25)</cell></row><row><cell>P-value</cell><cell>1.00</cell><cell>0.52</cell><cell>0.14</cell><cell>0.02</cell></row><row><cell>FIGO stage III/IV</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Progression-free/progressed, N</cell><cell>18/35</cell><cell>8/16</cell><cell>28/42</cell><cell>15/52</cell></row><row><cell>Negative b</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell><cell>1.0 (ref)</cell></row><row><cell>Positive b</cell><cell>0.97 (0.43-2.20)</cell><cell>0.38 (0.03-5.12)</cell><cell>0.78 (0.38-1.62)</cell><cell>1.20 (0.60-2.37)</cell></row><row><cell>P-value</cell><cell>0.94</cell><cell>0.47</cell><cell>0.51</cell><cell>0.60</cell></row></table><note>ab</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.bjcancer.com | DOI:10.1038/bjc.2014.567</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p>We wish to thank all of the patients, study centers and personnel who participated in this study. We gratefully acknowledge the contributions of the AOCS Group (http://www.aocstudy.org) ( </p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p>The authors declare no conflict of interest.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>MK and LEK designed the overall study and oversaw statistical analysis. SJR, DGH, MK and LEK obtained financial support. SJR and MPI coordinated the OTTA studies database. MK and JM reviewed histological slides. AD, BG and SEJ harmonised the clinical variables. MK, BAC, PDPP, SD, DDB, KO, UM, CM, SL, WB, LS, MWB, AH, FCT, AH, DLW, MSA, EH, AJ, CH, KRK, BLF, GLK, ZCF, RAV, SL, SC, GN, PG, AG-M, SAG, EB, MW, BR, MB, HM, AO, PS, MJ-L, KED, JA, MM, JMK, HS, CE, AD, GC-T, SF, BG, SEJ, JG, LG, ELG, SKK, DGH, PAF, KBM, JDB and LEK coordinated contributing studies. MK, JDB and LEK drafted the manuscript, and all authors contributed to the final draft.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">S</forename><surname>Anglesio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">S</forename><surname>Carey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Helen</forename><surname>Mackay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2011.01.005</idno>
		<idno type="PMID">21276610</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology</title>
		<title level="j" type="abbrev">Gynecologic Oncology</title>
		<idno type="ISSN">0090-8258</idno>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="407" to="415" />
			<date type="published" when="2011-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deborah</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Allen</forename><forename type="middle">J</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">C</forename><surname>Weil</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2013.03.002</idno>
		<idno type="PMID">23474348</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology</title>
		<title level="j" type="abbrev">Gynecologic Oncology</title>
		<idno type="ISSN">0090-8258</idno>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="452" to="458" />
			<date type="published" when="2013-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nyaladzi</forename><surname>Balogun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aleksandra</forename><surname>Gentry-Maharaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><forename type="middle">L</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anita</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andy</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeremy</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><surname>Burnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Widschwendter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sue</forename><forename type="middle">F</forename><surname>Gessler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><forename type="middle">J</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Usha</forename><surname>Menon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jclinepi.2010.07.008</idno>
		<idno type="PMID">21074968</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Epidemiology</title>
		<title level="j" type="abbrev">Journal of Clinical Epidemiology</title>
		<idno type="ISSN">0895-4356</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="525" to="530" />
			<date type="published" when="2011-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amy</forename><forename type="middle">B</forename><surname>Bromley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alon</forename><forename type="middle">D</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pamela</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jill</forename><forename type="middle">G</forename><surname>Nation</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregg</forename><forename type="middle">S</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Praful</forename><surname>Ghatage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guangming</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<idno type="DOI">10.1097/pgp.0b013e31824c2372</idno>
		<idno type="PMID">22833078</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Gynecological Pathology</title>
		<title level="j" type="abbrev">International Journal of Gynecological Pathology</title>
		<idno type="ISSN">0277-1691</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="397" to="404" />
			<date type="published" when="2012-09" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ethan</forename><surname>Cerami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianjiong</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ugur</forename><surname>Dogrusoz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benjamin</forename><forename type="middle">E</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Selcuk</forename><forename type="middle">Onur</forename><surname>Sumer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bülent</forename><forename type="middle">Arman</forename><surname>Aksoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anders</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caitlin</forename><forename type="middle">J</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">L</forename><surname>Heuer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erik</forename><surname>Larsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yevgeniy</forename><surname>Antipin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Boris</forename><surname>Reva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arthur</forename><forename type="middle">P</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chris</forename><surname>Sander</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nikolaus</forename><surname>Schultz</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.cd-12-0095</idno>
		<idno type="PMID">22588877</idno>
		<idno type="PMCID">PMC3956037</idno>
		<ptr type="open-access" target="https://cancerdiscovery.aacrjournals.org/content/candisc/2/5/401.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<title level="j" type="abbrev">Cancer Discovery</title>
		<idno type="ISSN">2159-8274</idno>
		<idno type="ISSNe">2159-8290</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="401" to="404" />
			<date type="published" when="2012-05" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Li</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ming-Cheng</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chia-Yen</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ying-Cheng</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Han-Wei</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chi-An</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Yao</forename><surname>Hsieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Fang</forename><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molonc.2011.11.010</idno>
		<idno type="PMID">22265591</idno>
		<idno type="PMCID">PMC5528335</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc5528335?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Molecular Oncology</title>
		<idno type="ISSN">1574-7891</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="360" to="369" />
			<date type="published" when="2011-12-20" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucia</forename><forename type="middle">M A</forename><surname>Crane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henriette</forename><forename type="middle">J G</forename><surname>Arts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marleen</forename><surname>Van Oosten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ate</forename><forename type="middle">G J</forename><surname>Van Der Zee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gooitzen</forename><forename type="middle">M</forename><surname>Van Dam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joost</forename><surname>Bart</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13402-011-0052-6</idno>
		<idno type="PMID">21647742</idno>
		<idno type="PMCID">PMC3268989</idno>
		<ptr type="open-access" target="https://link.springer.com/content/pdf/10.1007%2Fs13402-011-0052-6.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cellular Oncology</title>
		<title level="j" type="abbrev">Cell Oncol.</title>
		<idno type="ISSN">2211-3428</idno>
		<idno type="ISSNe">2211-3436</idno>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="9" to="18" />
			<date type="published" when="2011-06-07" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The distal fallopian tube: a new model for pelvic serous carcinogenesis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Crum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronny</forename><surname>Drapkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><surname>Miron</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tan</forename><forename type="middle">A</forename><surname>Ince</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Muto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">W</forename><surname>Kindelberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yonghee</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1097/gco.0b013e328011a21f</idno>
		<idno type="PMID">17218844</idno>
	</analytic>
	<monogr>
		<title level="j">Current Opinion in Obstetrics and Gynecology</title>
		<title level="j" type="abbrev">Current Opinion in Obstetrics and Gynecology</title>
		<idno type="ISSN">1040-872X</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="9" />
			<date type="published" when="2007-02" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Despierre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lambrechts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Leunen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Berteloot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Neven</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Amant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>O'shannessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">B</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Vergote</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2013.03.024</idno>
		<idno type="PMID">23558051</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology</title>
		<title level="j" type="abbrev">Gynecologic Oncology</title>
		<idno type="ISSN">0090-8258</idno>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="192" to="199" />
			<date type="published" when="2013-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Ebel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Routhier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Foley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jacob</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Mcdonough</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Turchin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">B</forename><surname>Kline</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Nicolaides</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Sass</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Grasso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Immun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">6</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><surname>Glud</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susanne</forename><forename type="middle">K</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Birthe</forename><forename type="middle">L</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claus</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lise</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Estrid</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johannes</forename><forename type="middle">E</forename><surname>Bock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><surname>Blaakaer</surname></persName>
		</author>
		<idno type="DOI">10.1001/archinte.164.20.2253</idno>
		<idno type="PMID">15534163</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/217611/ioi31034.pdf" />
	</analytic>
	<monogr>
		<title level="j">Archives of Internal Medicine</title>
		<title level="j" type="abbrev">Arch Intern Med</title>
		<idno type="ISSN">0003-9926</idno>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page">2253</biblScope>
			<date type="published" when="2004-11-08" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Goode</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Chenevix-Trench</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Fridley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Vierkant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">N</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Beesley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Johnatty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Armasu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">N</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Sicotte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kruger Kjaer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Fasching</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">B</forename><surname>Ekici</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Lambrechts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Despierre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Lundvall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">Y</forename><surname>Karlan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Chien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Duggan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-Y</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Phelan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">P</forename><surname>Peethambaram</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Schildkraut</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Shridhar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Sutphen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">J</forename><surname>Couch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Sellers</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.epi-11-0455</idno>
		<idno type="PMID">21724856</idno>
		<idno type="PMCID">PMC3153603</idno>
		<ptr type="open-access" target="http://cebp.aacrjournals.org/content/20/8/1638.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<title level="j" type="abbrev">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<idno type="ISSN">1055-9965</idno>
		<idno type="ISSNe">1538-7755</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1638" to="1648" />
			<date type="published" when="2011-07-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sumith</forename><forename type="middle">A</forename><surname>Kularatne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kimberly</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Franklyn</forename><forename type="middle">G</forename><surname>Prendergast</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">G</forename><surname>Klee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynn</forename><forename type="middle">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.23717</idno>
		<idno type="PMID">18661519</idno>
		<idno type="PMCID">PMC2778289</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2778289?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Int. J. Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1968" to="1973" />
			<date type="published" when="2008-10-15" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Hormone replacement therapy and prognosis in ovarian cancer patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><surname>Hein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Falk</forename><forename type="middle">C</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><forename type="middle">M</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">A</forename><surname>Fasching</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lothar</forename><surname>Häberle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">P</forename><surname>Lux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefan</forename><forename type="middle">P</forename><surname>Renner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sebastian</forename><forename type="middle">M</forename><surname>Jud</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">G</forename><surname>Schrauder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Wachter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johanna</forename><surname>Strehl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arndt</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><forename type="middle">W</forename><surname>Beckmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claudia</forename><surname>Rauh</surname></persName>
		</author>
		<idno type="DOI">10.1097/cej.0b013e328355ec22</idno>
		<idno type="PMID">22694828</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Cancer Prevention</title>
		<title level="j" type="abbrev">European Journal of Cancer Prevention</title>
		<idno type="ISSN">0959-8278</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="52" to="58" />
			<date type="published" when="2013-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Applied Survival Analysis: Regression Modeling of Time to Event Data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Hosmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Lameshow</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1999" />
			<publisher>John Wiley &amp; Sons Inc</publisher>
			<pubPlace>New York, NY, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Folate receptor alpha as a tumor target in epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kimberly</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ann</forename><forename type="middle">L</forename><surname>Oberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Teresa</forename><forename type="middle">J H</forename><surname>Christianson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keith</forename><forename type="middle">L</forename><surname>Knutson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynn</forename><forename type="middle">C</forename><surname>Hartmann</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2007.11.020</idno>
		<idno type="PMID">18222534</idno>
		<idno type="PMCID">PMC2707764</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2707764?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology</title>
		<title level="j" type="abbrev">Gynecologic Oncology</title>
		<idno type="ISSN">0090-8258</idno>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="619" to="626" />
			<date type="published" when="2008-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">A</forename><surname>Kamen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Smith</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00280-012-1890-2</idno>
		<idno type="PMID">22644798</idno>
		<idno type="ark">ark:/67375/VQC-475VH4B5-S</idno>
		<idno type="istexId">DD8FA15BECA34EC7F2DA7694A4E130A4F58C95D7</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemotherapy and Pharmacology</title>
		<title level="j" type="abbrev">Cancer Chemother Pharmacol</title>
		<idno type="ISSN">0344-5704</idno>
		<idno type="ISSNe">1432-0843</idno>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="113" to="120" />
			<date type="published" when="2012-05-27" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Elwood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Portillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">C</forename><surname>Antony</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Najfeld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Finley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Waxman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Kolhouse</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci113469</idno>
		<idno type="PMID">3366900</idno>
		<idno type="PMCID">PMC442570</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/113469/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1398" to="1406" />
			<date type="published" when="1988-05-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linda</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.21712</idno>
		<idno type="PMID">16453285</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Int. J. Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="243" to="250" />
			<date type="published" when="2006" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Differentially Methylated Loci Distinguish Ovarian Carcinoma Histological Types: Evaluation of a DNA Methylation Assay in FFPE Tissue</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linda</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angela</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soreh</forename><surname>Taghaddos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Irina</forename><surname>Dinu</surname></persName>
		</author>
		<idno type="DOI">10.1155/2013/815894</idno>
		<idno type="PMID">24175302</idno>
		<idno type="PMCID">PMC3794544</idno>
		<ptr type="open-access" target="http://downloads.hindawi.com/journals/bmri/2013/815894.pdf" />
	</analytic>
	<monogr>
		<title level="j">BioMed Research International</title>
		<title level="j" type="abbrev">BioMed Research International</title>
		<idno type="ISSN">2314-6133</idno>
		<idno type="ISSNe">2314-6141</idno>
		<imprint>
			<biblScope unit="volume">2013</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2013" />
			<publisher>Hindawi Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Multivitamin and Alcohol Intake and Folate Receptor Expression in Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Sellers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">L</forename><surname>Lingle</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.epi-05-0260</idno>
		<idno type="PMID">16172227</idno>
		<ptr type="open-access" target="http://cebp.aacrjournals.org/content/cebp/14/9/2168.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<title level="j" type="abbrev">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<idno type="ISSN">1055-9965</idno>
		<idno type="ISSNe">1538-7755</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2168" to="2172" />
			<date type="published" when="2005-09-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keith</forename><forename type="middle">L</forename><surname>Knutson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">J</forename><surname>Krco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Courtney</forename><forename type="middle">L</forename><surname>Erskine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karin</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linda</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Wettstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynn</forename><forename type="middle">C</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kimberly</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2006.05.9311</idno>
		<idno type="PMID">16908932</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="4254" to="4261" />
			<date type="published" when="2006-09-10" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Niki</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><surname>Mckinney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erika</forename><surname>Mehl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chana</forename><surname>Palmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nathan</forename><forename type="middle">J</forename><surname>Bowen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diana</forename><forename type="middle">N</forename><surname>Ionescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashish</forename><surname>Rajput</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leah</forename><forename type="middle">M</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dianne</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><surname>Swenerton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Blake</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Huntsman</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pmed.0050232</idno>
		<idno type="PMID">19053170</idno>
		<idno type="PMCID">PMC2592352</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.0050232&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS Medicine</title>
		<title level="j" type="abbrev">PLoS Med</title>
		<idno type="ISSNe">1549-1676</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">e232</biblScope>
			<date type="published" when="2008-12-02" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kobel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Duggan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">E</forename><surname>Kelemen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Fridley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Visscher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Vierkant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">B</forename><surname>Ness</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Moysich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Modugno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Bunker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Gentry-Maharaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><surname>Menon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Goode</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.epi-13-0391</idno>
		<idno type="PMID">23880734</idno>
		<idno type="PMCID">PMC3955399</idno>
		<ptr type="open-access" target="https://cebp.aacrjournals.org/content/cebp/22/10/1677.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<title level="j" type="abbrev">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<idno type="ISSN">1055-9965</idno>
		<idno type="ISSNe">1538-7755</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1677" to="1686" />
			<date type="published" when="2013-07-23" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Tumor Type and Substage Predict Survival in Stage I and II Ovarian Carcinoma: Insights and Implications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><forename type="middle">L</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Blake Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">D</forename><surname>Swenerton</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.ogx.0000371715.57006.04</idno>
	</analytic>
	<monogr>
		<title level="j">Obstetrical &amp; Gynecological Survey</title>
		<title level="j" type="abbrev">Obstetrical &amp; Gynecological Survey</title>
		<idno type="ISSN">0029-7828</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="232" to="234" />
			<date type="published" when="2010-04" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><surname>Reuss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><forename type="middle">Du</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefan</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Friedrich</forename><surname>Kommoss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dongxia</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Blake</forename><surname>Gilks</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.2744</idno>
		<idno type="PMID">20629008</idno>
		<idno type="ark">ark:/67375/WNG-HSC6Q451-W</idno>
		<idno type="istexId">FF62573848A5825AC16C7ED6A1DFD1072E373A25</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology</title>
		<title level="j" type="abbrev">J. Pathol.</title>
		<idno type="ISSN">0022-3417</idno>
		<imprint>
			<biblScope unit="volume">222</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="191" to="198" />
			<date type="published" when="2010-06-08" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Konner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Bell-Mcguinn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Sabbatini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Hensley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">P</forename><surname>Tew</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Pandit-Taskar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">V</forename><surname>Els</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Schweizer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Weil</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.ccr-10-0700</idno>
		<idno type="PMID">20855460</idno>
		<ptr type="open-access" target="http://clincancerres.aacrjournals.org/content/16/21/5288.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Clinical Cancer Research</title>
		<title level="j" type="abbrev">Clinical Cancer Research</title>
		<idno type="ISSN">1078-0432</idno>
		<idno type="ISSNe">1557-3265</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="5288" to="5295" />
			<date type="published" when="2010-09-20" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Folate-targeted chemotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">P</forename><surname>Leamon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Reddy</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.addr.2004.01.008</idno>
		<idno type="PMID">15094211</idno>
	</analytic>
	<monogr>
		<title level="j">Advanced Drug Delivery Reviews</title>
		<title level="j" type="abbrev">Advanced Drug Delivery Reviews</title>
		<idno type="ISSN">0169-409X</idno>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1127" to="1141" />
			<date type="published" when="2004-04-29" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Hsuan</forename><surname>Lo-Ciganic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Janice</forename><forename type="middle">C</forename><surname>Zgibor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Clareann</forename><forename type="middle">H</forename><surname>Bunker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kirsten</forename><forename type="middle">B</forename><surname>Moysich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">P</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberta</forename><forename type="middle">B</forename><surname>Ness</surname></persName>
		</author>
		<idno type="DOI">10.1097/ede.0b013e3182456ad3</idno>
		<idno type="PMID">22252409</idno>
		<idno type="PMCID">PMC3454462</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3454462?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Epidemiology</title>
		<title level="j" type="abbrev">Epidemiology</title>
		<idno type="ISSN">1044-3983</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="311" to="319" />
			<date type="published" when="2012-03" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">REporting recommendations for tumour MARKer prognostic studies (REMARK)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Douglas</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Willi</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheila</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Massimo</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejca.2005.03.032</idno>
		<idno type="PMID">16043346</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2361579?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">European Journal of Cancer</title>
		<title level="j" type="abbrev">European Journal of Cancer</title>
		<idno type="ISSN">0959-8049</idno>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1690" to="1696" />
			<date type="published" when="2005-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Melissa</forename><forename type="middle">A</forename><surname>Merritt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Adèle</forename><forename type="middle">C</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christina</forename><forename type="middle">M</forename><surname>Nagle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Penelope</forename><forename type="middle">M</forename><surname>Webb</surname></persName>
		</author>
		<idno type="DOI">10.1002/ijc.23017</idno>
		<idno type="PMID">17721999</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cancer</title>
		<title level="j" type="abbrev">Int. J. Cancer</title>
		<idno type="ISSN">0020-7136</idno>
		<idno type="ISSNe">1097-0215</idno>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="170" to="176" />
			<date type="published" when="2007" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Interaction of folate receptor with signaling molecules lyn and G(alpha) (i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Miotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bagnoli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tomassetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">I</forename><surname>Colnaghi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Canevari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="349" to="357" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Oral Contraceptives and the Risk of Hereditary Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">A</forename><surname>Narod</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harvey</forename><surname>Risch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roxana</forename><surname>Moslehi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne</forename><surname>Dørum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><surname>Neuhausen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hakan</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diane</forename><surname>Provencher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><surname>Radice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gareth</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><surname>Bishop</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Sébastien</forename><surname>Brunet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruce</forename><forename type="middle">A J</forename><surname>Ponder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><forename type="middle">G M</forename><surname>Klijn</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm199808133390702</idno>
		<idno type="PMID">9700175</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="424" to="428" />
			<date type="published" when="1998-08-13" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">Wendel</forename><surname>Naumann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edward</forename><forename type="middle">A</forename><surname>Sausville</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elzbieta</forename><surname>Kutarska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharad</forename><forename type="middle">A</forename><surname>Ghamande</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nashat</forename><forename type="middle">Y</forename><surname>Gabrail</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">E</forename><surname>Depasquale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elzbieta</forename><surname>Nowara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucy</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">H</forename><surname>Gersh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">G</forename><surname>Teneriello</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wael</forename><forename type="middle">A</forename><surname>Harb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Panagiotis</forename><forename type="middle">A</forename><surname>Konstantinopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">T</forename><surname>Penson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">T</forename><surname>Symanowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chandra</forename><forename type="middle">D</forename><surname>Lovejoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Leamon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">E</forename><surname>Morgenstern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">A</forename><surname>Messmann</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2013.49.7685</idno>
		<idno type="PMID">24127448</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Oncology</title>
		<title level="j" type="abbrev">JCO</title>
		<idno type="ISSN">0732-183X</idno>
		<idno type="ISSNe">1527-7755</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="4400" to="4406" />
			<date type="published" when="2013-12-10" />
			<publisher>American Society of Clinical Oncology (ASCO)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Expression of Folate Receptor-α (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">J</forename><surname>O’shannessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><forename type="middle">B</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Smale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yao-Shi</forename><surname>Fu</surname></persName>
		</author>
		<idno type="DOI">10.1097/pgp.0b013e3182774562</idno>
		<idno type="PMID">23518909</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Gynecological Pathology</title>
		<title level="j" type="abbrev">International Journal of Gynecological Pathology</title>
		<idno type="ISSN">0277-1691</idno>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="258" to="268" />
			<date type="published" when="2013-05" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nikki</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary</forename><forename type="middle">Jo</forename><surname>Turk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elaine</forename><surname>Westrick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">D</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Leamon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ab.2004.12.026</idno>
		<idno type="PMID">15745749</idno>
	</analytic>
	<monogr>
		<title level="j">Analytical Biochemistry</title>
		<title level="j" type="abbrev">Analytical Biochemistry</title>
		<idno type="ISSN">0003-2697</idno>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="284" to="293" />
			<date type="published" when="2005-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jurgen</forename><forename type="middle">M J</forename><surname>Piek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">J</forename><surname>Van Diest</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">P</forename><surname>Zweemer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jan</forename><forename type="middle">W</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ria</forename><forename type="middle">J J</forename><surname>Poort-Keesom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fred</forename><forename type="middle">H</forename><surname>Menko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johan</forename><forename type="middle">J P</forename><surname>Gille</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ans</forename><forename type="middle">P M</forename><surname>Jongsma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerard</forename><surname>Pals</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Kenemans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ren�</forename><forename type="middle">H M</forename><surname>Verheijen</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.1000</idno>
		<idno type="PMID">11745677</idno>
		<idno type="ark">ark:/67375/WNG-WQLPVHL2-9</idno>
		<idno type="istexId">3C8EB87D86C2320CEB865BC260E946835A441425</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology</title>
		<title level="j" type="abbrev">J. Pathol.</title>
		<idno type="ISSN">0022-3417</idno>
		<idno type="ISSNe">1096-9896</idno>
		<imprint>
			<biblScope unit="volume">195</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="451" to="456" />
			<date type="published" when="2001" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leah</forename><forename type="middle">M</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Klausen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><surname>Mckinney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><forename type="middle">L</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Challayne</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erika</forename><surname>Mehl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Blake</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ken</forename><surname>Swenerton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><forename type="middle">Aj</forename><surname>Aparicio</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-5-33</idno>
		<idno type="PMID">18005407</idno>
		<idno type="PMCID">PMC2200658</idno>
		<ptr type="open-access" target="https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/1741-7015-5-33" />
	</analytic>
	<monogr>
		<title level="j">BMC Medicine</title>
		<title level="j" type="abbrev">BMC Med</title>
		<idno type="ISSNe">1741-7015</idno>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">33</biblScope>
			<date type="published" when="2007-11-15" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">F</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Prabir</forename><forename type="middle">K</forename><surname>Chaudhuri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Manohar</forename><surname>Ratnam</surname></persName>
		</author>
		<idno type="DOI">10.1002/1097-0142(19940501)73:9&lt;2432::aid-cncr2820730929&gt;3.0.co;2-s</idno>
		<idno type="PMID">7513252</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<title level="j" type="abbrev">Cancer</title>
		<idno type="ISSN">0008-543X</idno>
		<idno type="ISSNe">1097-0142</idno>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2432" to="2443" />
			<date type="published" when="1994-05-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sohrab</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Janine</forename><surname>Senz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryan</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Blaise</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kimberly</forename><forename type="middle">C</forename><surname>Wiegand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gillian</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abdalnasser</forename><surname>Zayed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erika</forename><surname>Mehl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">E</forename><surname>Kalloger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryan</forename><surname>Giuliany</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erika</forename><surname>Yorida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Varhol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">D</forename><surname>Swenerton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dianne</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">B</forename><surname>Clement</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colleen</forename><surname>Crane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><surname>Madore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diane</forename><surname>Provencher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Defazio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jaswinder</forename><surname>Khattra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gulisa</forename><surname>Turashvili</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongjun</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">N Mark</forename><surname>Glover</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Vanderhyden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chengquan</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><forename type="middle">A</forename><surname>Parkinson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mercedes</forename><surname>Jimenez-Linan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">D L</forename><surname>Bowtell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne-Marie</forename><surname>Mes-Masson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">D</forename><surname>Brenton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><forename type="middle">A</forename><surname>Aparicio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Niki</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Hirst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Blake</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Marra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa0902542</idno>
		<idno type="PMID">19516027</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="2719" to="2729" />
			<date type="published" when="2009-06-25" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weiva</forename><surname>Sieh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><surname>Köbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Teri</forename><forename type="middle">A</forename><surname>Longacre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">D</forename><surname>Bowtell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Defazio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marc</forename><forename type="middle">T</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Estrid</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suha</forename><surname>Deen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicolas</forename><surname>Wentzensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kirsten</forename><forename type="middle">B</forename><surname>Moysich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">D</forename><surname>Brenton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Blaise</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Usha</forename><surname>Menon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Blake</forename><surname>Gilks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andre</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><surname>Madore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sian</forename><surname>Fereday</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joshy</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><surname>Galletta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Galina</forename><surname>Lurie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lynne</forename><forename type="middle">R</forename><surname>Wilkens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">E</forename><surname>Carney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pamela</forename><forename type="middle">J</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rayna</forename><forename type="middle">K</forename><surname>Matsuno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susanne</forename><forename type="middle">Krüger</forename><surname>Kjær</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Allan</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claus</forename><surname>Høgdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kimberly</forename><forename type="middle">R</forename><surname>Kalli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brooke</forename><forename type="middle">L</forename><surname>Fridley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><forename type="middle">L</forename><surname>Keeney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Vierkant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julie</forename><forename type="middle">M</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Louise</forename><forename type="middle">A</forename><surname>Brinton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hannah</forename><forename type="middle">P</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">E</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Montserrat</forename><surname>García-Closas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jolanta</forename><surname>Lissowska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kunle</forename><surname>Odunsi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carl</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shashikant</forename><surname>Lele</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wiam</forename><surname>Bshara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lara</forename><surname>Sucheston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mercedes</forename><surname>Jimenez-Linan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristy</forename><surname>Driver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jennifer</forename><surname>Alsop</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marie</forename><surname>Mack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Valerie</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">H</forename><surname>Rothstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barry</forename><forename type="middle">P</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marcus</forename><forename type="middle">Q</forename><surname>Bernardini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Helen</forename><surname>Mackay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amit</forename><surname>Oza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><forename type="middle">L</forename><surname>Wozniak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aleksandra</forename><surname>Gentry-Maharaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">V</forename><surname>Tinker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leah</forename><forename type="middle">M</forename><surname>Prentice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christine</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">S</forename><surname>Anglesio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sharon</forename><forename type="middle">E</forename><surname>Johnatty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Georgia</forename><surname>Chenevix-Trench</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alice</forename><forename type="middle">S</forename><surname>Whittemore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">Dp</forename><surname>Pharoah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ellen</forename><forename type="middle">L</forename><surname>Goode</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">G</forename><surname>Huntsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1470-2045(13)70253-5</idno>
		<idno type="PMID">23845225</idno>
		<idno type="PMCID">PMC4006367</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4006367?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">The Lancet Oncology</title>
		<title level="j" type="abbrev">The Lancet Oncology</title>
		<idno type="ISSN">1470-2045</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="853" to="862" />
			<date type="published" when="2013-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Soegaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Blaakaer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K</forename><surname>Kjaer</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.epi-07-0089</idno>
		<idno type="PMID">17548679</idno>
		<ptr type="open-access" target="http://cebp.aacrjournals.org/content/16/6/1160.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<title level="j" type="abbrev">Cancer Epidemiology Biomarkers &amp; Prevention</title>
		<idno type="ISSN">1055-9965</idno>
		<idno type="ISSNe">1538-7755</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1160" to="1166" />
			<date type="published" when="2007-06-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Common variants in mismatch repair genes and risk of invasive ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Honglin</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">J</forename><surname>Ramus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lydia</forename><surname>Quaye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">A</forename><surname>Dicioccio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><surname>Tyrer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emma</forename><surname>Lomas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Danielle</forename><surname>Shadforth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Estrid</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claus</forename><surname>Hogdall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Valerie</forename><surname>Mcguire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alice</forename><forename type="middle">S</forename><surname>Whittemore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Douglas</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruce</forename><forename type="middle">A J</forename><surname>Ponder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susanne</forename><forename type="middle">Kruger</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">D P</forename><surname>Pharoah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><forename type="middle">A</forename><surname>Gayther</surname></persName>
		</author>
		<idno type="DOI">10.1093/carcin/bgl089</idno>
		<idno type="PMID">16774946</idno>
		<idno type="ark">ark:/67375/HXZ-QN9832VW-D</idno>
		<idno type="istexId">A30F4D9206DD838D6566178766AE84B1D312F260</idno>
		<ptr type="open-access" target="https://academic.oup.com/carcin/article-pdf/27/11/2235/17284905/bgl089.pdf" />
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<idno type="ISSN">0143-3334</idno>
		<idno type="ISSNe">1460-2180</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2235" to="2242" />
			<date type="published" when="2006-06-13" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Farletuzumab in epithelial ovarian carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Whitney</forename><forename type="middle">A</forename><surname>Spannuth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anil</forename><forename type="middle">K</forename><surname>Sood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">L</forename><surname>Coleman</surname></persName>
		</author>
		<idno type="DOI">10.1517/14712591003592069</idno>
		<idno type="PMID">20092424</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Opinion on Biological Therapy</title>
		<title level="j" type="abbrev">Expert Opinion on Biological Therapy</title>
		<idno type="ISSN">1471-2598</idno>
		<idno type="ISSNe">1744-7682</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="431" to="437" />
			<date type="published" when="2010-01-22" />
			<publisher>Informa Healthcare</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Integrated genomic analyses of ovarian carcinoma</title>
	</analytic>
	<monogr>
		<title level="m">The Cancer Genome Atlas Research Network</title>
		<imprint>
			<date type="published" when="2011" />
			<biblScope unit="volume">474</biblScope>
			<biblScope unit="page" from="609" to="615" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gooitzen</forename><forename type="middle">M</forename><surname>Van Dam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><surname>Themelis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lucia</forename><forename type="middle">M A</forename><surname>Crane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Niels</forename><forename type="middle">J</forename><surname>Harlaar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rick</forename><forename type="middle">G</forename><surname>Pleijhuis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wendy</forename><surname>Kelder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Athanasios</forename><surname>Sarantopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johannes</forename><forename type="middle">S</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henriette</forename><forename type="middle">J G</forename><surname>Arts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ate</forename><forename type="middle">G J</forename><surname>Van Der Zee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joost</forename><surname>Bart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philip</forename><forename type="middle">S</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vasilis</forename><surname>Ntziachristos</surname></persName>
		</author>
		<idno type="DOI">10.1038/nm.2472</idno>
		<idno type="PMID">21926976</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Medicine</title>
		<title level="j" type="abbrev">Nat Med</title>
		<idno type="ISSN">1078-8956</idno>
		<idno type="ISSNe">1546-170X</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1315" to="1319" />
			<date type="published" when="2011-09-18" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Immunohistochemical Reactivity of a Monoclonal Antibody Prepared against Human Ovarian Carcinoma on Normal and Pathological Female Genital Tissues</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rosalia</forename><surname>Veggian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Silvano</forename><surname>Fasolato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sylvie</forename><surname>Ménard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daria</forename><surname>Minucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><surname>Pizzetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><surname>Regazzoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elda</forename><surname>Tagliabue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><forename type="middle">Ines</forename><surname>Colnaghi</surname></persName>
		</author>
		<idno type="DOI">10.1177/030089168907500524</idno>
		<idno type="PMID">2481353</idno>
	</analytic>
	<monogr>
		<title level="j">Tumori Journal</title>
		<title level="j" type="abbrev">Tumori Journal</title>
		<idno type="ISSN">0300-8916</idno>
		<idno type="ISSNe">2038-2529</idno>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="510" to="513" />
			<date type="published" when="1989-10" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christen</forename><forename type="middle">L</forename><surname>Walters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rebecca</forename><forename type="middle">C</forename><surname>Arend</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deborah</forename><forename type="middle">K</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">Wendel</forename><surname>Naumann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">D</forename><surname>Alvarez</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2013.07.080</idno>
		<idno type="PMID">23863359</idno>
	</analytic>
	<monogr>
		<title level="j">Gynecologic Oncology</title>
		<title level="j" type="abbrev">Gynecologic Oncology</title>
		<idno type="ISSN">0090-8258</idno>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="493" to="498" />
			<date type="published" when="2013-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emma</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stewart</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lindy</forename><surname>Durrant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suha</forename><surname>Deen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00428-012-1252-9</idno>
		<idno type="PMID">22699808</idno>
		<idno type="ark">ark:/67375/VQC-VBHW64WV-8</idno>
		<idno type="istexId">BCD8F5AE725D7A5421E72C1F36E0067A1C6620D7</idno>
	</analytic>
	<monogr>
		<title level="j">Virchows Archiv</title>
		<title level="j" type="abbrev">Virchows Arch</title>
		<idno type="ISSN">0945-6317</idno>
		<idno type="ISSNe">1432-2307</idno>
		<imprint>
			<biblScope unit="volume">461</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="33" to="39" />
			<date type="published" when="2012-06-15" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Gunning</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ratnam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">9</biblScope>
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Unported</forename><surname>License</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
